System and method for enhancing cardiac signal sensing by cardiac pacemakers through genetic treatment

ABSTRACT

Delivery systems for and methods of delivering ion channel protein genetic material to cardiac cells in areas adjacent to where an electrode is to be positioned in a patient&#39;s heart to improve or correct the signal to noise ratio of cardiac signals, such as the P-wave, is described herein. More specifically, there is provided a system and method for delivering sodium ion channel proteins or nucleic acid molecules encoding sodium ion channel proteins to a site in the heart adjacent to an electrode to increase the expression of the same, thereby enhancing the cardiac signal amplitude and enabling improved sensing of cardiac signals by an implanted pacemaker.

This application is a continuation of application Ser. No. 08/682,433,filed Jul. 17, 1996 now abandoned.

FIELD OF THE INVENTION

The present invention relates to systems for and methods of geneticallyenhancing cardiac signals for use by cardiac pacemakers and, moreparticularly, for enhancing the signal to noise ratio of atrial P-wavesfor improved pacemaker sensing.

BACKGROUND OF THE INVENTION

The cardiac pacemaker is a widely used device for treating variouscardiac disorders, e.g., sick sinus syndrome, “brady-tachy syndrome” andheart block. The basic function of the pacemaker is to deliver stimuluspulses to one or more of the patient's heart chambers, as and whenneeded, to initiate cardiac depolarizations and thus maintain a desiredheart rate, or to affect improvements in cardiac output for patients inheart failure. In addition to delivering stimulus pulses, anotherimportant feature is the sensing of a patient's heartbeat signals, whenthey occur spontaneously, for purposes of controlling the stimulus pulsedelivery. Thus, the demand pacemaker inhibits delivery of a stimuluspulse and resets the pulse generator in the event of sensing a timelyspontaneous beat, i.e., a P-wave which is an atrial depolarization, or aQRS, or just R-wave, which is a ventricular depolarization. For example,an AAI mode pacemaker both paces and senses in just the atrium, andinhibits delivery of a pace pulse if a timely P-wave is sensed. Theinhibit operation necessarily depends upon reliably sensing spontaneousP-waves. In a dual chamber pacemaker, both the P-wave and R-wave aresensed. As examples of dual chamber pacemakers, see U.S. Pat. Nos.4,920,965; 4,539,991; and 4,554,921, incorporated herein by reference. Aparticular purpose of the dual chamber pacemaker may be to treat a blockcondition, where the patient's natural pacemaker is operating normally,causing timely atrial contractions, but the depolarization signal is notefficiently propagated to the ventricle so as to cause a followingventricular contraction. In such a situation, the dual chamber pacemakeris designed to sense the P-wave, and deliver a synchronized ventricularstimulus pulse, i.e., a pulse which stimulates the ventricle after atimed AV delay which approximates the AV delay of a healthy heart. It isseen that reliable sensing of the P-wave is vital to this type of dualchamber pacing.

In yet another type of pacemaker operation, the pacemaker operates inwhat is referred to a VDD mode, meaning that it paces only in theventricle, but senses both P-waves and R-waves, i.e., has single chamberpacing but dual chamber sensing. The advantage of this mode is that onlyone lead need be positioned in the patient's heart, since no pacingpulses are delivered to the atrium. The VDD lead has the normalelectrode or electrode pair at its distal end, for positioning in theventricle; and it has a “floating” electrode (or electrode pair)proximal to the tip and positioned so that it is located in the atrium,for sensing the P-wave. See, for example, U.S. Pat. No. 5,127,694.However, since such a floating electrode is not necessarily embeddedinto or positioned adjacent the myocardium, the sensed P-wave is not asstrong as for the case where a separate atrial lead is used, andconsequently, the reliability of sensing the P-wave is even less.

Atrial sensing is additionally considered to be a significant problembecause of the low P-wave amplitudes commonly available and the presenceof relatively large far field QRS and other “noise” signals. It iscommonly accepted that atrial P-wave amplitudes are relatively lowcompared to ventricular R-waves because of the differences in musclemass near the electrodes. That is, ventricular R-waves are large becausethere is a large volume of myocardium around the electrode, whereas theatrial signal is small because the underlying tissue is relatively thin.Thus, for any pacing system which senses the P wave, such as an AAIpacer or any dual sense mode pacer, reliably sensing P-waves is a majorproblem for which improvement has long been sought.

With regard to the source of the P-wave, it is noted that it is not themuscle itself that is sensed, but the electric potentials resulting fromthe depolarization of several myocardial cells, i.e., a net positive ionflow into myocardial cells through specialized membrane proteins calledvoltage-gated ion channels, such as the sodium channels. More musclemass means there are more membrane channels in the area adjacent to theelectrodes. However, the muscle mass adjacent to the atrial electrodecannot be increased. But the P-wave could be enhanced if the number ofconducting membrane channels within the adjacent muscle mass can beincreased. Sodium channels are transmembrane proteins responsible forthe rapid transport of Na⁺ ions across cell membranes underlying thedepolarization of the action potential in many types of cells. Inparticular, cardiac fast sodium channels are responsible for the fastupstroke or phase 0 of the action potential in myocardial cells.Fozzard, et al., Circ. Res., 1985, 56, 475-485. Recently, a humancardiac voltage-dependent sodium channel, hH1, has been cloned,sequenced, and functionally expressed. Gellens, et al., Proc. Natl.Acad. Sci. USA, 1992, 89, 554-558.

Gene therapy has also recently emerged as a powerful approach totreating a variety of mammalian diseases. Direct transfer of geneticmaterial into myocardial tissue in vivo has recently been demonstratedto be an effective method of expressing a desired protein. For example,direct myocardial transfection of plasmid DNA by direct injection intothe heart of rabbits and pigs (Gal, et al., Lab. Invest., 1993, 68,18-25), as well as of rats (Acsadi, et al., The New Biol., 1991, 3,71-81), has been shown to result in expression of particular reportergene products. In addition, direct in vivo gene transfer into myocardialcells has also been accomplished by directly injecting adenoviralvectors into the myocardium. French, et al., Circulation, 1994, 90,2415-2424, and PCT Publication WO 94/11506.

Pursuant to the above, this invention provides a system and method ofenhancing the cardiac pacemaker atrial and/or ventricular sensingfunction, i.e., enhancing the signal to noise ratio of cardiac signals,and in particular the sensed P-wave, through concurrent genetictreatment whereby the number of ion channels responsible fordepolarization of the atrial or ventricular myocardial cells isincreased. Applicants' invention is directed to introducing ion channelprotein genetic material into myocardial cells adjacent to or closest tothe position of the atrial or ventricular electrode. In any particularapplication, the genetic material is placed so as to provide maximumbenefit for sensing P-waves, or other cardiac signals, with the pacinglead used, i.e., for an AAI pacing system, a lead which is fixatedagainst the atrial wall.

SUMMARY OF THE INVENTION

In accordance with the above, a primary purpose of Applicants' claimedinvention is to provide methods and delivery systems for enhancingcardiac pacemaker signal sensing. In a particular embodiment, theclaimed invention provides methods and delivery systems for enhancingcardiac pacemaker P-wave sensing. Upon identifying a patient in whichthe signal to noise ratio for atrial or ventricular sensing isproblematic, ion channel protein genetic material is selected such thatexpression of a selected ion channel protein in cells adjacent to theposition of the atrial or ventricle electrode corrects or improves thesignal to noise ratio for cardiac signal sensing. Preferably, expressionof a selected ion channel protein can improve or correct the signal tonoise ratio for cardiac signal sensing in either or both the ventriclesand atria of all persons with pacemakers, especially those persons whichhave been diagnosed with a low signal to noise ratio for P-wave sensing.Improvement or correction of P-wave sensing can be manifested by anincrease in the amplitude of the P-wave, or other characteristic of thecardiac signal, thus resulting in an increase of the signal to noiseratio of the signal sensed in the pacemaker atrial sensing channel.Delivery of the ion channel protein genetic material can be accomplishedby adaptation of available pacing leads, such as, for example, AAI orDDD leads, as well as by specific modification of leads and catheters.Delivery of the genetic material may be affected by a pump or may bepassive.

The ion channel protein genetic material used in the system and methodof this invention comprises recombinant nucleic acid moleculescomprising a nucleic acid molecule encoding the ion channel proteininserted into a delivery vehicle, such as, for example, plasmids oradenoviral vectors, and the appropriate regulatory elements.Alternatively, the ion channel protein genetic material comprises theion channel protein itself. Expression of the desired ion channelprotein from recombinant nucleic acid molecules is controlled bypromoters, preferably cardiac tissue-specific promoter-enhancers,operably linked to the nucleic acid molecule encoding the ion channelprotein. The conduction protein is preferably a sodium ion channelprotein, such as, for example, the voltage-dependent sodium channel hH1,which is used to correct or improve the signal to noise ratio of cardiacsignals, and in particular, atrial P-wave sensing. The ion channelprotein genetic material is delivered to specific sites adjacent to theatrial or ventricular electrode within the heart by perfusion orinjection of a therapeutically effective amount, which is that amountwhich corrects or improves the signal to noise ratio of the cardiacsignal of the myocardial cells adjacent to the electrode. Thetherapeutically effective amount can be delivered to the specific sitein the heart in a single dose or multiple doses, as desired.

In carrying out the treatment provided by this invention, the patient'ssignal to noise ratio for a particular cardiac signal, such as, forexample, P-wave sensing, is first studied to determine whether suchcardiac signal sensing is adequate or, rather, whether the patientpresents a condition requiring adjustment, which is addressable bygenetically modifying the particular cardiac signal amplitude ofmyocardial cells adjacent the atrial or ventricular electrode inaccordance with this invention. However, in a preferred embodiment, allpatients with pacemakers may receive the treatment described herein toimprove the cardiac signal sensing by their pacemakers. The appropriateion channel protein genetic material is then selected, which stepincludes selection of the nucleic acid molecule encoding the ion channelprotein, delivery vehicle, and the appropriate regulatory elements,etc., as noted above. It is also determined what dose is indicated fortreating the problematic cardiac signal to noise ratio depending uponthe extent of the noise that is diagnosed, and whether follow-uptreatments require implantation of an externally controllable deliverysystem. The determined ion channel protein genetic material is prepared,and loaded into the delivery system. The treatment is then effected byutilizing the delivery system to deliver the therapeutic dose to thepatient, e.g., either injecting the material or perfusing the selectedarea of the heart adjacent the atrial or ventricular electrode. Afterthis genetic treatment, the patient is paced in a standard manner, e.g.,AAI pacing or dual chamber synchronous pacing which includes sensing thepatient's P-waves and delivering synchronized ventricular stimuluspulses, such as in the VDD or DDD mode.

The present invention further provides a delivery system for deliveringa therapeutically effective amount of a predetermined ion channelprotein genetic material to an identified cardiac location adjacent theatrial or ventricular electrode, the genetic material being selected foramplifying the particular cardiac signal, such as, for example, theP-wave, from cardiac cells to which it is delivered, thus improving orcorrecting the cardiac signal to noise ratio received by the sensingelectrode. The delivery system includes the selected genetic materialcontained in a reservoir, and a catheter or electrode subsystem fordelivering the genetic material from the reservoir to the identifiedcardiac location so as to contact a plurality of cells in the proximityof the sensing electrode.

The delivery system may utilize an external reservoir for providing thegenetic material, or alternately may utilize an implantable reservoir.In either embodiment, a controllable pump mechanism may be provided fortransferring therapeutic doses of the genetic material from thereservoir, through a catheter or electrode, and to the selected cardiaclocation. The pump may be a mini or micro pump located within thedelivery system. Alternatively, rather than using a pump mechanism, theion channel protein genetic material can be passively delivered to theappropriate location adjacent the appropriate electrode. The cathetersubsystem may be of a type for direct introduction into the myocardium,as with a transthoracic procedure, or, more preferably, a endocardialcatheter having a distal tip portion adapted for positioning andinjecting the genetic material into the myocardium from within a heartchamber. In a preferred embodiment, the catheter distal tip has anormally withdrawn helical needle, which is extendable when positionedin the vicinity of the selected site so as to be screwed into the heart.The needle is hollow and connects with the catheter lumen so as toreceive the pumped genetic material; it has one or more ports located soas to effectively release the genetic material for transduction into thecardiac area adjacent the sensing electrode. In the case of an electrodesubsystem, an implantable electrode is used in place of the cathetersubsystem, which is able to deliver drugs, such as steroids, or otherbioactive agents, such as, for example, ion channel protein geneticmaterial. Such implantable electrodes with drug dispensing capabilitiesare set forth in U.S. Pat. Nos. 4,711,251, 5,458,631, 4,360,031, and5,496,360, each of which are incorporated herein by reference. Thedelivery system can be used for one treatment and then removed, or canbe implanted for subsequent treatments, in which latter case it iscontrollable by an external programmer type device. In anotherembodiment, the catheter or electrode subsystem may be combined with apacing lead for sensing the patient's cardiac signals and for providingstimulus pulses.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flow diagram presenting the primary steps involved in thepractice of this invention, including selecting an appropriate geneticmaterial, positioning delivery system against the heart wall, andexpressing the genetic material in an appropriate dose into thedetermined location.

FIG. 2 is a schematic representation of a delivery system in accordancewith this invention, illustrating delivery of genetic material into apatient's heart at the chosen location using a catheter subsystem.

FIG. 3 is a schematic drawing of the distal portion of a catheter whichcan be used for injecting a solution carrying chosen genetic materialinto a patient's heart.

FIG. 4 illustrates the distal end of a catheter, having a distal portionwhich encloses an osmotic pump.

FIG. 5A is a schematic representation of a delivery system in accordancewith this invention, having a combined catheter and pacing lead, with aseparate pump; FIG. 5B is another embodiment of a combined pacing leadand delivery catheter having a reservoir located at the distal end ofthe catheter.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Applicants' invention provides methods and delivery systems forcorrecting or improving cardiac signal sensing, especially the signal tonoise ratio of the atrial P-wave, thus enhancing pacemaker sensing. Aproblematic signal to noise ratio for P-waves results from a naturallylow amplitude P-wave generated in the atrium, noise from the ventricularQRS complex, muscle noise, noise from other sources, or a combinationthereof. The signal to noise ratio is determined by routine andconventional techniques known to the skilled artisan. Once the specificproblem has been identified in a particular patient, e.g., in anypatient with a pacemaker or who is to receive a pacemaker, ion channelprotein genetic material is selected such that expression of a selectedion channel protein corrects or improves the cardiac signal amplitude,thus improving or correcting the cardiac signal to noise ratio. The ionchannel protein genetic material comprises either the ion channelprotein itself or recombinant nucleic acid molecules comprising anucleic acid molecule encoding the ion channel protein inserted into adelivery vehicle, such as, for example, plasmid, cosmid, YAC vector,viral vectors, and the like, and the appropriate regulatory elements. Inpreferred embodiments of the present invention, the nucleic acidmolecule encoding the ion channel protein is the full length codingsequence cDNA of an ion channel protein, and is inserted into a plasmidor adenoviral vector, such as, for example, pGEM3 or pBR322, and Ad5,respectively. The regulatory elements are capable of directingexpression in mammalian cells, specifically human cells. The regulatoryelements include a promoter and a polyadenylation signal. Expression ofthe desired ion channel protein is preferably controlled by cardiactissue-specific promoter-enhancers, operably linked to the nucleic acidmolecule encoding the ion channel protein. The ion channel protein ispreferably a sodium channel protein, such as, for example, the hH1voltage-regulated sodium channel, which is used to correct or improvethe cardiac signal to noise ratio. The ion channel protein geneticmaterial is preferably delivered in a pharmaceutical compositioncomprising, for example, the ion channel protein genetic material in avolume of phosphate-buffered saline with 5% sucrose. In someembodiments, the ion channel protein genetic material is delivered withgenetic material encoding the Na⁺/K⁺ pump, which is also inserted intoan appropriate delivery vehicle. The ion channel protein geneticmaterial may also be delivered separately or in combination with class Iand class IV antiarrhythmic drugs, which have been shown to increasesodium channel mRNA expression. The ion channel protein genetic materialis delivered to specific sites within the heart, adjacent to the atrialor ventricular electrode, by perfusion or injection of a therapeuticallyeffective amount, which is that amount which corrects or improves thecardiac signal to noise ratio. Preferably, the therapeutically effectiveamount corrects or improves the P-wave signal to noise ratio. Thetherapeutically effective amount can be delivered to the specific sitein the heart in single or multiple doses, as desired, using the deliverysystems of the invention.

The present invention also comprises a delivery system for delivering atherapeutically effective amount of ion channel protein genetic materialto a specific cardiac location, adjacent the atrial or ventricularelectrode, in such a way as to enhance the amplitude of the cardiacsignal, thus improving or correcting the signal to noise ratio. In afirst embodiment, the delivery system basically comprises a reservoirsubsystem for holding the genetic material, and a catheter subsystem incommunication with the reservoir subsystem for placement of the geneticmaterial in and around the identified cardiac location. In anotherembodiment, the delivery system basically comprises a reservoirsubsystem for holding the genetic material, and an electrode subsystemin communication with the reservoir subsystem for placement of thegenetic material in and around the identified cardiac location. As seenin the following discussion of several preferred embodiments, thereservoir subsystem and catheter subsystem or electrode subsystem may beseparate, or they may be combined. Preferably the reservoir contains upto 25 ml of a genetic material for delivery to the myocardium. In someapplications, only a bolus of about 0.1-10 ml, or more preferably 1-5ml, is delivered to the targeted areas. In other applications, such aswhere ion channel protein is being delivered in repeated doses, 25 ml ormore may be used. Also, the genetic material may be diluted in a salinesolution, such as, for example, phosphate-buffered saline (PBS), thereservoir holding the diluted solution for controlled delivery.Additionally, it is to be understood that the reservoir and associatedcontrol apparatus may be either implantable or external to the body,depending upon the circumstances, e.g., whether metered doses are to beadministered to the patient over a period of time, or whether thedelivery of the genetic material is essentially a one time treatment.

Referring now to FIG. 1, the primary steps involved in the practice ofthis invention are shown in the flow diagram. The illustrated steps areperformed following the initial diagnosis of a patient with aproblematic P-wave signal to noise ratio, which can result from a lowamplitude P-wave generated in the atrium, noise from the ventricular QRScomplex, noise from other sources, or a combination thereof. Diagnosiscan be accomplished, for example, by electrocardiography procedures.Preferably, the steps are performed in connection with all patientshaving cardiac pacemakers. As illustrated in block 30, the next step isto select the appropriate ion channel protein genetic material. Thisselection yields the “preselected genetic material.” The ion channelprotein genetic material is next prepared, as illustrated in block 31,by either inserting the nucleic acid molecules encoding the appropriateion channel protein into a delivery vehicle with the appropriateregulatory elements, in the case of a recombinant nucleic acid molecule,or expressing the ion channel protein from an expression vector, in thecase of the ion channel protein itself. As shown in block 32, the nextstep is to prepare and load the delivery system with a therapeuticallyeffective amount of the ion channel protein genetic material. Asillustrated in block 33, the next step comprises inserting the catheter,or other delivery subsystem, such as, for example, the electrodesubsystem, into the patient's heart and positioning it against the heartwall. As shown in block 34, the next step comprises administering thetherapeutically effective amount to the patient by contacting theappropriate location in the heart, adjacent to the atrial or ventricularelectrode, using the delivery system described herein. An alternativemethod of administering the therapeutically effective amount of the ionchannel protein genetic material is to directly inject the heart of thepatient. The next step, shown in block 35, is to pace the patient in astandard manner, e.g., dual chamber synchronous pacing which includessensing the patient's P-waves and delivering synchronized ventricularstimulus pulses, or AAI pacing. In accordance with this step, it may bepreferable to adjust the sensitivity of the atrial or ventricularsensing channel in accordance with the observed cardiac signalamplitude. The final step 36, which is optional, is to evaluate theresponse of the patient to the treatment by, for example, measuring theamplitude of the cardiac signal, such as, for example, the P-wave, byconventional electrocardiographic techniques, such as, for example, bytelemetry from the implanted pulse generator. The sensitivity can thenbe adjusted accordingly.

Referring now to FIG. 2, there is shown an illustrative embodiment of adelivery system useful for certain applications of this invention, e.g.,where larger amounts of genetic material alone or in solution areemployed. A catheter 38, preferably a transvenous catheter, includes anelongated catheter body 40, suitably an insulative outer sheath whichmay be made of polyurethane, Teflon, silicone, or any other acceptablebiocompatible plastic. The catheter has a standard lumen (illustrated inFIG. 3) extending therethrough for the length thereof, whichcommunicates through to a hollow helical needle element 44, which isadapted for screwing into the patient's myocardium. The outer distal endof helical element 44 is open or porous, thus permitting geneticmaterial in fluid form to be dispensed out of the end, as is discussedin more detail below in connection with FIG. 3. At the proximal end ofthe catheter, a fitting 46 is located, to which a Luer lock 48 iscoupled. Luer lock 48 is coupled to the proximal end of sheath 40 andreceives the lumen. A swivel mount 50 is mounted to Luer lock 48,allowing rotation of the catheter relative to Luer lock 52. Luer lock 52in turn is coupled through control element 54 to a tube 58 whichcommunicates with reservoir 55, suitably through flow control 57 andfilter 56. Reservoir 55 holds a supply of the selected genetic material.Control elements 57 and 54 are used for adjustment of the pressure andflow rate, and may be mechanically or electronically controlled. Thus,unit 54 or 57 may be used to control either rate of delivery, or dosagesize, or both. Control unit 54 may be programmed to automaticallyrelease predetermined doses on a timed basis. Further, for an implantedsystem, control unit 54 may be activated from an external programmer asillustrated at 53. Reference is made to international applicationpublished under the PCT, International Publication No. WO 95/05781,incorporated herein by reference, for a more detailed description ofsuch a reservoir and catheter combination. It is to be understood thatsuch a system is useful for this invention primarily for applicationswhere larger fluid mounts are to be expressed, e.g., where a dilutedsaline solution is used to wash or perfuse a selected area.

Referring now to FIG. 3, there is shown in expanded detail a schematicof the distal end of the catheter of FIG. 2, illustrating theinterconnection of the helical element 44 with the interior of thecatheter. As illustrated, the helical needle 44 is provided with aninternal lumen 59 which is in communication with the internal lumen 63Lof the lead formed by tube 63. In this embodiment, helical element 44may also be a pacing electrode, in which case it is formed of conductivematerial and welded, or otherwise fastened, to tip element 61. Tipelement 61 in turn is electrically connected to coil or coils 64, 65,which extend the length of the lead and are connected to a pacemaker. Anouter membrane 60 forms the outer wall of elongated catheter body 40,shown in FIG. 2. Further referring to FIG. 3, element 44 has an outlet75 where the genetic material may be expressed, and holes or ports 76,77, and 78 may also be utilized for providing exits for the geneticmaterial which is supplied through lumen 59 under a suitable pressure ofzero up to about one atmosphere from reservoir 55 (shown in FIG. 2) andthe control elements.

In practice, a catheter 38 of the form illustrated in FIGS. 2 and 3 isadvanced to the desired site for treatment, eg, adjacent the site wherethe sensing electrode is to be positioned. The catheter may be guided tothe indicated location by being passed down a steerable or guidablecatheter having an accommodating lumen, for example as disclosed in U.S.Pat. No. 5,030,204; or by means of a fixed configuration guide cathetersuch as illustrated in U.S. Pat. No. 5,104,393. Alternately, thecatheter may be advanced to the desired location within the heart bymeans of a deflectable stylet, as disclosed in PCT Patent Application WO93/04724, published Mar. 18, 1993, or by a deflectable guide wire asdisclosed in U.S. Pat. No. 5,060,660. In yet another embodiment, thehelical element 44 may be ordinarily retracted within a sheath at thetime of guiding the catheter into the patient's heart, and extended forscrewing into the heart by use of a stylet. Such extensible helicalarrangements are well known in the pacing art, and are commerciallyavailable.

It is to be understood that other forms of the reservoir subsystems andcatheter subsystems are within the scope of this invention. Reservoirembodiments include, for example, drug dispensing irrigatableelectrodes, such as those described in U.S. Pat. No. 4,360,031;electrically controllable, non-occluding, body implanting drug deliverysystem, such as those described in U.S. Pat. No. 5,041,107; implantabledrug infusion reservoir such as those described in U.S. Pat. No.5,176,641; medication delivery devices such as those described in U.S.Pat. No. 5,443,450; infusion pumps, such as SYNCHROMED7 made byMedtronic, Inc.; and osmotic pumps, such as those made by Alza.

Referring now to FIG. 4, there is shown, by way of illustration, anotherembodiment of a delivery system having a combined catheter andreservoir, useful for applications involving delivery of a relativelysmall bolus of genetic material, e.g., 1-5 ml. FIG. 4 illustrates thedistal end of a catheter, having a distal portion 70 which encloses anosmotic pump. See U.S. Pat. No. 4,711,251, assigned to Medtronic, Inc.,incorporated herein by reference. The pump includes an inner chamber 68and an outer chamber 66, which chambers are separated by an impermeablemembrane 67. A semi-permeable outer membrane 72 forms the outer wall ofchamber 66. The tubular portion 74 of the helical member connects tolumen 74L within inner chamber 68. A conductor 80, which runs the lengthof the catheter, extends into the inner chamber 68 and connects withextension 74E as shown at 74C to provide electrical contact through toelement 44, in an application which the element 44 is used as a pacingelectrode. An insulating cover 86 encompasses the conductor 80 from thepoint of contact with the semi-permeable outer membrane 72 distally. Aseal 79 is provided at the point where the conductor passes throughouter membrane 72 and inner membrane 67. An end cap 73, which may beintegral with outer membrane 72 closes the chamber. Alternately, end cap73 may be constructed to elute a predetermined medication, such as, forexample, steroids. Steroids, such as dexamethasone sodium phosphate,beclamethasone, and the like, are used to control inflammatoryprocesses.

In this arrangement, prior to inserting the catheter distal end into thepatient's heart, the inner chamber 68 is charged with the geneticmaterial which is to be dispensed into the myocardium. This may be done,for example, by simply inserting a micro needle through end cap 73, andinserting the desired bolus of genetic material into chamber 68. Afterthe chamber 68 is filled and the is catheter is implanted, body fluidswill enter chamber 66 through membrane 72 to impart a pressure on theinner chamber 68 via the impermeable membrane 67. This results in adispensing of the genetic material stored within chamber 68 through thelumen 74L of extension 74E and through the outlet 75 of the helicalelement 44. Although the preferred needle or element 44 is helical,additional configurations of needles or elements can also be used asknown to those skilled in the art.

Still referring now to FIG. 4, there is illustrated another embodimentof a catheter tip useful for delivering a small bolus of the selectedgenetic material. In this embodiment, the bolus of material is storedwithin the hollow interior of distal needle 44, i.e., the interior isthe reservoir. The interior reservoir is maintained sealed by use of asoluble material which is normally solid, but which dissolves whensubjected to body fluids for a period of time. An example of suchmaterial is mannitol. Plugs or globules 81-85 of mannitol areillustrated (by dashed lines) in place to block the two ends of element44, as well as the ports 76, 77, 78. This may be combined with anosmotic pump, as described in connection with FIG. 3, where the outerchamber is filled with a saline solution which forces the geneticmaterial out of the ports of element 44. Another alternate embodiment,not shown, is to use a stylet which inserted through to the distal endof the catheter, to push a piston which aids in expressing the geneticmaterial into the myocardial cells. Alternatively, the piston can bedriven by a micro pump. In another embodiment, the genetic materialcontacts the myocardial cells by passive delivery.

Referring now to FIG. 5A, there is shown, by way of illustration,another embodiment of an implantable delivery system comprising acombined pacing lead and delivery catheter, hereinafter referred tosimply as a catheter. In this embodiment, the catheter 90 is combinedwith a pacemaker or pulse generator (not shown) and a source of geneticmaterial such as illustrated by pump 92 which is suitably implanted nearthe pacemaker. The proximal end 91 of the catheter is connected to thepacemaker in the standard fashion. The genetic material is deliveredthrough connecting tube 93 to a proximal section 88 of the catheter,communicating with lengthwise catheter lumen illustrated at 89.Alternately, the pacemaker head may contain a reservoir and micropump,for providing delivery of the genetic material directly to the lumen 89.The main length of the catheter has an outside sheath of biocompatibleinsulating material 96, and at least one conductor coil 95 whichcommunicates electrically from the pacemaker to electrode 97 at thedistal tip of the catheter. The catheter further comprises an axiallypositioned polymeric cannula 94, having lumen 87, through at least aportion of the catheter length and positioned within coil 95, whichprovides an inner surface for the catheter lumen. The cannula terminatesat the distal end of the catheter, just proximal to the tip portion ofelectrode 97, which is illustrated as having an outer porous surface.Electrode 97 has a central opening, shown covered with the porouselectrode material, through which genetic material can pass when thecatheter is positioned in the patient. As shown, conductor coil 95 iselectrically connected to electrode 97, and connects pace pulses andsensed cardiac signals between the pacemaker and the electrode. Ofcourse, for a bipolar embodiment, the lead/catheter 90 carries a secondelectrode (not shown), suitably a ring electrode just proximal toelectrode 97. Also, as illustrated, a fixation mechanism such as tines98 are employed for fixing or anchoring the distal tip to the heart wallof the patient.

In one embodiment, pump 92 is suitably an osmotic minipump, which pumpsfluid contained within through tube 93, into catheter portion 88 andthrough the lumens 89, 87 to the tip electrode 97. As mentionedpreviously, the reservoir and pump may alternately be mounted in thepacemaker device itself. In either instance, the genetic material isdelivered under very minimal pressure from the reservoir through thelumen of the catheter to the electrode, where it is passed through theelectrode central channel to contact myocardial cells. In yet anotherembodiment, the lumen portion 87 provided by the cannula is utilized asthe reservoir. In this embodiment, delivery may either be passive, orwith the aid of a micropump (not shown). The genetic material can bepreloaded into the cannula, or it can be inserted by a needle justbefore the catheter is introduced and positioned with the patient.

In another embodiment, as illustrated in FIG. 5B, a chamber 99 isprovided just proximal from eluting electrode 97, and serves as thereservoir of the genetic material. Insulating material 96 is formed froma self-sealing material such that it may be pierced with a needle, orthe like, and reseal itself, thus allowing introduction of the geneticmaterial into the chamber prior to implantation. Alternately, insulatingmaterial 96 can contain a port (not shown) through which the needleinserts the genetic material. In this embodiment, delivery of thematerial is without a pump, i.e., passive, the material draining slowlythrough the microporous portion of electrode 97.

The above described delivery systems can be used, for example, inmethods of pacing and enhancing the detectability of sensed cardiacsignals. A supply of a genetic material of the class having the propertyof increasing the expression of ion channels in cardiac cells to whichit is delivered is selected. A transvenous catheter, having proximal anddistal ends and a pacing electrode at the distal end, is introduced intothe patient. The distal end of the catheter is positioned against thepatient's heart wall and the genetic material is delivered through thecatheter and out of the distal end, to the cardiac cells adjacent thepacing electrode, thereby enhancing cardiac signals produced by thecells. Normal cardiac pacing is carried out with the pacemaker andconnected catheter implanted in the patient.

Although a transvenous form of delivery system is preferred, it is to beunderstood that the invention can employ other methods and devices. Forexample, a small bolus of selected genetic material can be loaded into amicro-syringe, e.g., a 100 μl Hamilton syringe, and applied directlyfrom the outside of the heart.

As used herein, the phrase cardiac signal refers to any cardiac signalthat is detectable and includes, but is not limited to, the P-wave.

As used herein, the phrase “signal to noise ratio” refers to the ratioof the amplitude of the cardiac signal, such as, for example, theP-wave, to the amplitude of the “noise.” In addition, the signal tonoise ratio can be measured for other cardiac signals as well. Sourcesof “noise” include, but are not limited to, the QRS complex and musclenoise. It is desirable to establish a high signal to noise ratio, i.e.,a signal to noise ratio of greater than 1:1 for unipolar leads andgreater than 3:1 for bipolar leads. It is even more preferred toestablish a signal to noise ratio greater than 10:1.

As used herein, the phrase “ion channel protein genetic material” refersto recombinant nucleic acid molecules encoding an ion channel proteinor, alternatively, an ion channel protein itself, which is used in themethods and delivery systems of the invention. For chronic treatment, orlong term treatment, the ion channel protein genetic material will be inthe form of recombinant nucleic acid molecules encoding the ion channelprotein. In contrast, for acute treatment, or short term treatment, theion channel protein genetic material will be in the form of the ionchannel proteins themselves.

A “recombinant nucleic acid molecule”, as used herein, is comprised ofan isolated ion channel protein-encoding nucleotide sequence insertedinto a delivery vehicle. Regulatory elements, such as the promoter andpolyadenylation signal, are operably linked to the nucleotide sequenceencoding the ion channel protein, whereby the protein is capable ofbeing produced when the recombinant nucleic acid molecule is introducedinto a cell.

The nucleic acid molecules encoding the ion channel proteins areprepared synthetically or, preferably, from isolated nucleic acidmolecules, as described below. A nucleic acid is “isolated” whenpurified away from other cellular constituents, such as, for example,other cellular nucleic acids or proteins, by standard techniques knownto those of ordinary skill in the art. The coding region of the nucleicacid molecule encoding the ion channel protein can encode a full lengthgene product or a subfragment thereof, or a novel mutated or fusionsequence. The protein coding sequence can be a sequence endogenous tothe target cell, or exogenous to the target cell. The promoter, withwhich the coding sequence is operably associated, may or may not be onethat normally is associated with the coding sequence.

The nucleic acid molecule encoding the ion channel protein is insertedinto an appropriate delivery vehicle, such as, for example, anexpression plasmid, cosmid, YAC vector, and the like. Almost anydelivery vehicle can be used for introducing nucleic acids into thecardiovascular system, including, for example, recombinant vectors, suchas one based on adenovirus serotype 5, Ad5, as set forth in French, etal., Circulation, 1994, 90, 2414-2424, which is incorporated herein byreference. An additional protocol for adenovirus-mediated gene transferto cardiac cells is set forth in WO 94/11506, Johns, J. Clin. Invest.,1995, 96, 1152-1158, and in Barr, et al., Gene Ther., 1994, 1, 51-58,both of which are incorporated herein by reference. Other recombinantvectors include, for example, plasmid DNA vectors, such as one derivedfrom pGEM3 or pBR322, as set forth in Acsadi, et al., The New Biol.,1991, 3, 71-81, and Gal, et al., Lab. Invest., 1993, 68, 18-25, both ofwhich are incorporated herein by reference, cDNA-containing liposomes,artificial viruses, nanoparticles, and the like. It is also contemplatedthat ion channel proteins be injected directly into the myocardium.

The regulatory elements of the recombinant nucleic acid molecules of theinvention are capable of directing expression in mammalian cells,specifically human cells. The regulatory elements include a promoter anda polyadenylation signal. In addition, other elements, such as a Kozakregion, may also be included in the recombinant nucleic acid molecule.Examples of polyadenylation signals useful to practice the presentinvention include, but are not limited to, SV40 polyadenylation signalsand LTR polyadenylation signals. In particular, the SV40 polyadenylationsignal which is in pCEP4 plasmid (Invitrogen, San Diego, Calif.),referred to as the SV40 polyadenylation signal, can be used.

The promoters useful in constructing the recombinant nucleic acidmolecules of the invention may be constitutive or inducible. Aconstitutive promoter is expressed under all conditions of cell growth.Exemplary constitutive promoters include the promoters for the followinggenes: hypoxanthine phosphoribosyl transferase (HPRT), adenosinedeaminase, pyruvate kinase, β-actin, human myosin, human hemoglobin,human muscle creatine, and others. In addition, many viral promotersfunction constitutively in eukaryotic cells, and include, but are notlimited to, the early and late promoters of SV40, the Mouse MammaryTumor Virus (MMTV) promoter, the long terminal repeats (LTRs) of Maloneyleukemia virus, Human Immunodeficiency Virus (HIV), Cytomegalovirus(CMV) immediate early promoter, Epstein Barr Virus (EBV), Rous SarcomaVirus (RSV), and other retroviruses, and the thymidine kinase promoterof herpes simplex virus. Other promoters are known to those of ordinaryskill in the art.

Inducible promoters are expressed in the presence of an inducing agent.For example, the metallothionein promoter is induced to promote(increase) transcription in the presence of certain metal ions. Otherinducible promoters are known to those of ordinary skill in the art.

Promoters and polyadenylation signals used must be functional within thecells of the mammal. In order to maximize protein production, regulatorysequences may be selected which are well suited for gene expression inthe cardiac cells into which the recombinant nucleic acid molecule isadministered. For example, the promoter is preferably a cardiactissue-specific promoter-enhancer, such as, for example, cardiac isoformtroponin C (cTNC) promoter. Parmacek, et al., J. Biol. Chem., 1990, 265,15970-15976, and Parmacek, et al., Mol. Cell Biol., 1992, 12, 1967-1976.In addition, codons may be selected which are most efficientlytranscribed in the cell. One having ordinary skill in the art canproduce recombinant nucleic acid molecules which are functional in thecardiac cells.

Genetic material can be introduced into a cell or “contacted” by a cellby, for example, transfection or transduction procedures. Transfectionrefers to the acquisition by a cell of new genetic material byincorporation of added nucleic acid molecules. Transfection can occur byphysical or chemical methods. Many transfection techniques are known tothose of ordinary skill in the art including: calcium phosphate DNAco-precipitation; DEAE-dextran DNA transfection; electroporation; nakedplasmid adsorption, and cationic liposome-mediated transfection.Transduction refers to the process of transferring nucleic acid into acell using a DNA or RNA virus. Suitable viral vectors for use astransducing agents include, but are not limited to, retroviral vectors,adeno associated viral vectors, vaccinia viruses, and Semliki Forestvirus vectors.

Treatment of cells, or contacting cells, with recombinant nucleic acidmolecules can take place in vivo or ex vivo. For ex vivo treatment,cells are isolated from an animal (preferably a human), transformed(i.e., transduced or transfected in vitro) with a delivery vehiclecontaining a nucleic acid molecule encoding an ion channel protein, andthen administered to a recipient. Procedures for removing cells frommammals are well known to those of ordinary skill in the art. Inaddition to cells, tissue or the whole or parts of organs may beremoved, treated ex vivo and then returned to the patient. Thus, cells,tissue or organs may be cultured, bathed, perfused and the like underconditions for introducing the recombinant nucleic acid molecules of theinvention into the desired cells.

For in vivo treatment, cells of an animal, preferably a mammal and mostpreferably a human, are transformed in vivo with a recombinant nucleicacid molecule of the invention. The in vivo treatment may involvesystemic intravenous treatment with a recombinant nucleic acid molecule,local internal treatment with a recombinant nucleic acid molecule, suchas by localized perfusion or topical treatment, and the like. Whenperforming in vivo administration of the recombinant nucleic acidmolecule, the preferred delivery vehicles are based on noncytopathiceukaryotic viruses in which nonessential or complementable genes havebeen replaced with the nucleic acid sequence of interest. Suchnoncytopathic viruses include retroviruses, the life cycle of whichinvolves reverse transcription of genomic viral RNA into DNA withsubsequent proviral integration into host cellular DNA. Retroviruseshave recently been approved for human gene therapy trials. Most usefulare those retroviruses that are replication-deficient (i.e., capable ofdirecting synthesis of the desired proteins, but incapable ofmanufacturing an infectious particle). Such genetically alteredretroviral expression vectors have general utility for high-efficiencytransduction of genes in vivo. Standard protocols for producingreplication-deficient retroviruses (including the steps of incorporationof exogenous genetic material into a plasmid, transfection of apackaging cell line with plasmid, production of recombinant retrovirusesby the packaging cell line, collection of viral particles from tissueculture media, and infection of the target cells with viral particles)are provided in Kriegler, M. “Gene Transfer and Expression, a LaboratoryManual”, W. H. Freeman Co., New York (1990) and Murry, E. J. e.d.“Methods in Molecular Biology”, Vol. 7, Humana Press, Inc., Clifton,N.J. (1991).

A preferred virus for contacting cells in certain applications, such asin in vivo applications, is the adeno-associated virus, adouble-stranded DNA virus. The adeno-associated virus can be engineeredto be replication deficient and is capable of infecting a wide range ofcell types and species. It further has advantages such as heat and lipidsolvent stability, high transduction frequencies in cells of diverselineages, including hemopoietic cells, and lack of superinfectioninhibition thus allowing multiple series of transductions. Recentreports indicate that the adeno-associated virus can also function in anextrachromosomal fashion.

In preferred embodiments of the present invention, the recombinantnucleic acid molecules comprising nucleic acid molecules encoding theion channel proteins, or, in the alternative, the ion channel proteins,are delivered to cardiac cells adjacent the atrial or ventricularelectrode, or both, using the delivery systems set forth above.Alternatively, the ion channel protein genetic material is delivered tothe cardiac cells by direct injection.

In preferred embodiments of the present invention, the nucleic acidmolecules encoding the ion channel proteins comprise the full lengthcoding sequence cDNA of an ion channel protein. Preferably, the ionchannel proteins are sodium channel proteins; more preferably, the ionchannel protein is the voltage-regulated sodium channel hH1. Such anucleic acid molecule is described in the Gellens, et al., Proc. Natl.Acad. Sci. USA, 1992, 89, 554-558, and White, et al., Mol. Pharmacol.,1991, 39, 604-608 references, both of which are incorporated herein byreference, which contain the full length amino acid sequence and cDNAsequence, respectively.

Introduction of the ion channel-encoding nucleic acid molecules or theion channel proteins to cardiac cells adjacent the atrial or ventricularelectrode will result in increased expression of sodium channels,producing a larger cardiac signal, such as, for example, P-wave, andthus, an improved or corrected signal to noise ratio. Nucleic acidmolecules comprising nucleotide sequences encoding hH1 sodium channelare isolated and purified according to the methods set forth in Gellens,et al., Proc. Natl. Acad. Sci. USA, 1992, 89, 554-558, and White, etal., Mol. Pharmacol., 1991, 39, 604-608. The nucleic acid and proteinsequences of hH1 sodium channel are set forth in SEQ ID NO:1 and SEQ IDNO:2, respectively. It is contemplated that nucleic acid moleculescomprising nucleotide sequences that are preferably at least 70%homologous, more preferably at least 80% homologous, and most preferablyat least 90% homologous to the ion channel nucleotide sequencesdescribed in SEQ ID NO:1 can also be used.

It is understood that minor modifications of nucleotide sequence or theprimary amino acid sequence may result in proteins which havesubstantially equivalent or enhanced activity as compared to the ionchannel proteins exemplified herein. These modifications may bedeliberate, as through site-directed mutagenesis, or may be accidentalsuch as through mutations in hosts which produce the ion channelproteins. A “mutation” in a protein alters its primary structure(relative to the commonly occurring or specifically described protein)due to changes in the nucleotide sequence of the DNA which encodes it.These mutations specifically include allelic variants. Mutationalchanges in the primary structure of a protein can result from deletions,additions, or substitutions. A “deletion” is defined as a polypeptide inwhich one or more internal amino acid residues are absent as compared tothe native sequence. An “addition” is defined as a polypeptide which hasone or more additional internal amino acid residues as compared to thewild type protein. A “substitution” results from the replacement of oneor more amino acid residues by other residues. A protein “fragment” is apolypeptide consisting of a primary amino acid sequence which isidentical to a portion of the primary sequence of the protein to whichthe polypeptide is related.

Preferred “substitutions” are those which are conservative, i.e.,wherein a residue is replaced by another of the same general type. As iswell understood, naturally-occurring amino acids can be subclassified asacidic, basic, neutral and polar, or neutral and nonpolar and/oraromatic. It is generally preferred that encoded peptides differing fromthe native form contain substituted codons for amino acids which arefrom the same group as that of the amino acid replaced. Thus, ingeneral, the basic amino acids Lys, Arg, and Histidine areinterchangeable; the acidic amino acids Asp and Glu are interchangeable;the neutral polar amino acids Ser, Thr, Cys, Gln, and Asn areinterchangeable; the nonpolar aliphatic acids Gly, Ala, Val, Ile, andLeu are conservative with respect to each other (but because of size,Gly and Ala are more closely related and Val, Ile and Leu are moreclosely related), and the aromatic amino acids Phe, Trp, and Tyr areinterchangeable.

While Pro is a nonpolar neutral amino acid, it represents difficultiesbecause of its effects on conformation, and substitutions by or for Proare not preferred, except when the same or similar conformationalresults can be obtained. Polar amino acids which represent conservativechanges include Ser, Thr, Gln, Asn; and to a lesser extent, Met. Inaddition, although classified in different categories, Ala, Gly, and Serseem to be interchangeable, and Cys additionally fits into this group,or may be classified with the polar neutral amino acids. Somesubstitutions by codons for amino acids from different classes may alsobe useful.

Once the nucleic acid molecules encoding the ion channel proteins areisolated and purified according to the methods described above,recombinant nucleic acid molecules are prepared in which the desired ionchannel nucleic acid molecule is incorporated into a delivery vehicle bymethods known to those skilled in the art, as taught in, for example,Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Ed. ColdSpring Harbor Press (1989). Preferred delivery vehicles include, forexample, plasmids (Acsadi, et al., The New Biol., 1991, 3, 71-81, andGal, et al., Lab. Invest., 1993, 68, 18-25, both of which areincorporated herein by reference) and adenovirus (WO 94/11506, Johns, J.Clin. Invest., 1995, 96, 1152-1158, and in Barr, et al., Gene Ther.,1994, 1, 51-58, each of which are incorporated herein by reference). Thenucleic acid molecules encoding ion channel proteins, or ion channelproteins produced therefrom, are delivered to the cardiac cells adjacentto the atrial electrode by the delivery systems of the presentinvention. Thus, such delivery systems of the present invention are usedto contact the cardiac cells adjacent the atrial electrode withrecombinant nucleic acid molecules encoding an ion channel protein, orion channel proteins.

Where the ion channel protein genetic material is in the form of ionchannel proteins, such proteins can be prepared in large quantities byusing various standard expression systems known to those skilled in theart. Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Ed.Cold Spring Harbor Press (1989), pp. 16.1-16.55, incorporated herein byreference.

The recombinant nucleic acid molecules or ion channel proteins arepreferably delivered in a pharmaceutical composition. Suchpharmaceutical compositions can include, for example, the recombinantnucleic acid molecule or protein in a volume of phosphate-bufferedsaline with 5% sucrose. In other embodiments of the invention, therecombinant nucleic acid molecule or protein is delivered with suitablepharmaceutical carriers, such as those described in the most recentedition of Remington's Pharmaceutical Sciences, A. Osol, a standardreference text in this field. The recombinant nucleic acid molecule orprotein is delivered in a therapeutically effective amount. Such amountis determined experimentally and is that amount which either improves orcorrects the P-wave signal to noise ratio by enhancing the P-waveamplitude as a result of the increased expression of sodium channels inthe cardiac cells adjacent the atrial or ventricular electrode. Theamount of recombinant nucleic acid molecule or protein is preferablybetween 0.01 μg and 100 mg, more preferably between 0.1 μg and 10 mg,more preferably between 1 μg and 1 mg, and most preferably between 10 μgand 100 μg. A single therapeutically effective amount is referred to asa bolus. Where adenovirus vectors are used, the amount of recombinantnucleic acid molecule is preferably between 10⁷ plaque forming units(pfu) and 10¹⁵ pfu, more preferably between 10⁸ pfu and 10¹⁴ pfu, andmost preferably between 10⁹ pfu and 10¹² pfu. A single therapeuticallyeffective amount of ion channel protein genetic material is referred toas a bolus. In some embodiments of the present invention, the deliveryof the recombinant nucleic acid molecules or proteins is combined withsteroid elution, such as with dexamethasone sodium phosphate,beclamethasone, and the like, to control inflammatory processes.

In some embodiments of the invention, it may be preferred to administer,in addition to ion channel protein genetic material, delivery vehicleencoding the Na⁺/K⁺ pump. The Na⁺/K⁺ pump acts to discharge Na⁺ ionsfrom the myocardial cells that have accumulated as a result of theintroduction of the ion channel protein genetic material. This treatmentcan be optional, as determined by the skilled practitioner. cDNAencoding the alpha and beta subunits of the human Na⁺/K⁺ pump are setforth in Kawakami, et al., J. Biochem., 1986, 100, 389-397, andKawakami, et al., Nuc. Acids Res., 1986, 14, 2833-2844, both of whichare incorporated herein by reference. The nucleic acid and amino acidsequences for the alpha subunit are set forth in SEQ ID NO:5 and SEQ IDNO:6, respectively. The nucleic acid and amino acid sequences for thebeta subunit are set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively.The delivery vehicles for the pump subunits can be constructed from cDNAlibraries in the same manner as set forth for hH1, except that theforward primer 5′-ATGGGGAAGGGGGTTGGACGTGAT-3′ (SEQ ID NO:9) and reverseprimer 5′-ATAGTAGGTTTCCTTCTCCACCCA-3′ (SEQ ID NO:10) for the alphasubunit, and the forward primer 5′-ATGGCCCGCGGGAAAGCCAAGGAG-3′ (SEQ IDNO:11)and reverse primer 5′-GCTCTTAACTTCAATTTTTACATC-3′ (SEQ ID NO:12)for the beta subunit are used. It is understood that other primers canbe used in addition to those set forth herein, as is well known to theskilled artisan. A therapeutically effective amount of the geneticmaterial encoding the Na⁺/K⁺ pump is delivered to the myocardial cellsusing the delivery systems described herein. The therapeuticallyeffective amount is determined by the practitioner, and depends upon theresults achieved with the ion channel protein genetic material.

In preferred embodiments of the invention, the recombinant nucleic acidmolecules encoding the ion channel proteins is delivered with class Iand/or class IV antiarrhythmic drugs, such as, for example, verapamil,mexiletine, and the like, or combinations thereof. These drugs may bedelivered subcutaneously, intravenously, injected in the immediatevicinity of the atrial electrode, or as determined by the skilledartisan. These drugs may be delivered by one injection, or in multipleinjections. The amount of antiarrhythmic drugs depends upon the age,weight, sex, and other characteristics of the patient, and is determinedempirically by the skilled artisan. Class I and/or class IVantiarrhythmic drugs have been shown to enhance sodium ion channelexpression in mammals. Duff, et al., Mol. Pharmacol., 1992, 42, 570-574,and Taouis, et al., J. Clin. Invest., 1991, 88, 375-378, both of whichare incorporated herein by reference.

The following examples are meant to be exemplary of the preferredembodiments of the invention and are not meant to be limiting.

EXAMPLES Example 1

Isolation and Purification of Nucleic Acid Molecule Encoding hH1

Nucleic acid molecules encoding hH1 are isolated and purified accordingto general methods well known to those skilled in the art, and inparticular, by the method set forth in Gellens, et al., Proc. Natl.Acad. Sci. USA, 1992, 89, 554-558, incorporated herein by reference.Briefly, a size selected and random-primed adult human cardiac cDNAlibrary constructed in λZAPII (Stratagene) is screened with cDNA probescorresponding to nucleotides 1-4385 and 5424-7076 derived from the ratmuscle TTX-I isoform (rSkM2), as set forth in Kallen, et al., Neuron,1990, 4, 233-242, incorporated herein by reference. Hybridizations areperformed at 42EC for 18 hours in 50% formamide, 5×SSPE, 5×Denhardt'ssolution, 0.1% SDS/salmon sperm DNA, random primed ³²P-labeled probe.Filters are washed with 6×standard saline citrate, 0.1% SDS at 65EC.Plaque purified clones are rescued as pBluescript phagemids andsequenced as described in Kallen, et al., Neuron, 1990, 4, 233-242. Afull-length hH1 construct is made in pBluescript by sequential ligationof S14 EcoR1-Sac II (nt +1 to +252), C75 Sac II-KpnI (nt +253 to +4377),and C92 KpnI-EcoR1 (nt +4378 to +8491) fragments and the full lengthinsert is moved into a modified pSP64T vector, as set forth in White, etal., Mol. Pharmacol., 1991, 39, 604-608, incorporated herein byreference. Nucleotides −151 to −8 of the 5′ untranslated region aredeleted from the construct using exonuclease III and mung bean nuclease,as set forth in White, et al., Mol. Pharmacol., 1991, 39, 604-608.

Alternatively, cDNA for hH1 may be prepared from fresh cardiac tissue.Briefly, total cellular RNA is isolated and purified (Chomczynsky, etal., Anal. Biochem., 1987, 162, 156-159) from heart tissue, obtainedfrom cardiac transplantation donors, or from salvaged tissue, andselected for poly(A) RNA (Sambrook et al., Molecular Cloning: ALaboratory Manual, Second Ed. Cold Spring Harbor Press (1989), pp.7.26-7.29). cDNA corresponding to the hH1 sodium channel protein isprepared from the poly(A) cardiac RNA by reverse transcription using aGENEAMP™ PCR kit (Perkin Elmer Cetus, Norwalk, Conn.), or the like,using random hexamers according to the manufacturer's instructions. Thespecific hH1 nucleic acid molecules are amplified by the polymerasechain reaction (PCR), also using the GENEAMP™ PCR kit, or the like,using forward and reverse primers specific for hH1 according to themanufacturer's instructions. For example, the forward primer for cloninghH1 is preferably 5′-ATGGCAAACTTCCTATTACCTCGG-3′ (SEQ ID NO:3), and thereverse primer is 5′-CACGATGGACTCACGGTCCCTGTC-3′ (SEQ ID NO:4). It isunderstood that additional primers can be used for amplification asdetermined by those skilled in the art. These primers may be preceded atthe 5′ terminus by nucleotide sequences containing endonucleaserestriction sites for easy incorporation into vectors. The specific ionchannel nucleic acid molecules can also be amplified by PCR from humangenomic DNA (Stratagene, San Diego, Calif.). After cutting the PCRproducts with the appropriate restriction endonuclease(s), the PCRproducts are purified by phenol:chloroform extractions, or usingcommercial purification kits, such as, for example, MAGIC™ Minipreps DNAPurification System (Promega, Madison, Wis.). The specific nucleotidesequence of the PCR products is determined by conventional DNAsequencing procedures, and the identity of the PCR products confirmed bycomparison to the published sequences for the ion channel proteins.

Example 2

Insertion of Ion Channel cDNA into Delivery Vehicles

Preferably, ion channel cDNA is inserted into either plasmid oradenoviral vectors. Plasmid vectors include for example, pGEM3 orpBR322, as set forth in Acsadi, et al., The New Biol., 1991, 3, 71-81,and Gal, et al., Lab. Invest., 1993, 68, 18-25. Adenoviral vectorsinclude for example, adenovirus serotype 5, Ads, as set forth in French,et al., Circulation, 1994, 90, 2414-2424, and Johns, J. Clin. Invest.,1995, 96, 1152-1158.

Preferably, the primers used to amplify the ion channel nucleic acidmolecules are designed with unique endonuclease restriction siteslocated at the 5′ terminus. In the absence of such design, polylinkerarms, containing unique restriction sites, can be ligated thereto. Aftercutting the purified PCR products with the appropriate restrictionendonuclease(s), the plasmid vector, comprising a polylinker, is alsocut with the same restriction endonuclease(s), affording the ion channelnucleic acid molecule a site at which to ligate. In a similar manner,recombinant adenovirus (Gluzman, et al., in Eukaryotic Viral Vectors,Gluzman, ed., Cold Spring Harbor Press, 1982, pp.187-192, French, etal., Circulation, 1994, 90, 2414-2424, and Johns, J. Clin. Invest.,1995, 96, 1152-1158) containing ion channel cDNA molecules are preparedin accordance with standard techniques well known to those skilled inthe art.

It is contemplated that variations of the above-described invention maybe constructed that are consistent with the spirit of the invention.

12 6048 bases nucleic acid double linear 1 ATG GCA AAC TTC CTA TTA CCTCGG GGC ACC AGC AGC TTC CGC AGG 45 Met Ala Asn Phe Leu Leu Pro Arg GlyThr Ser Ser Phe Arg Arg 1 5 10 15 TTC ACA CGG GAG TCC CTG GCA GCC ATCGAG AAG CGC ATG GCG GAG 90 Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu LysArg Met Ala Glu 20 25 30 AAG CAA GCC CGC GGC TCA ACC ACC TTG CAG GAG AGCCGA GAG GGG 135 Lys Gln Ala Arg Gly Ser Thr Thr Leu Gln Glu Ser Arg GluGly 35 40 45 CTG CCC GAG GAG GAG GCT CCC CGG CCC CAG CTG GAC CTG CAG GCC180 Leu Pro Glu Glu Glu Ala Pro Arg Pro Gln Leu Asp Leu Gln Ala 50 55 60TCC AAA AAG CTG CCA GAT CTC TAT GGC AAT CCA CCC CAA GAG CTC 225 Ser LysLys Leu Pro Asp Leu Tyr Gly Asn Pro Pro Gln Glu Leu 65 70 75 ATC GGA GAGCCC CTG GAG GAC CTG GAC CCC TTC TAT AGC ACC CAA 270 Ile Gly Glu Pro LeuGlu Asp Leu Asp Pro Phe Tyr Ser Thr Gln 80 85 90 AAG ACT TTC ATC GTA CTGAAT AAA GGC AAG ACC ATC TTC CGG TTC 315 Lys Thr Phe Ile Val Leu Asn LysGly Lys Thr Ile Phe Arg Phe 95 100 105 AGT GCC ACC AAC GCC TTG TAT GTCCTC AGT CCC TTC CAC CCA GTT 360 Ser Ala Thr Asn Ala Leu Tyr Val Leu SerPro Phe His Pro Val 110 115 120 CGG AGA GCG GCT GTG AAG ATT CTG GTT CACTCG CTC TTC AAC ATG 405 Arg Arg Ala Ala Val Lys Ile Leu Val His Ser LeuPhe Asn Met 125 130 135 CTC ATC ATG TGC ACC ATC CTC ACC AAC TGC GTG TTCATG GCC CAG 450 Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe Met AlaGln 140 145 150 CAC GAC CCT CCA CCC TGG ACC AAG TAT GTC GAG TAC ACC TTCACC 495 His Asp Pro Pro Pro Trp Thr Lys Tyr Val Glu Tyr Thr Phe Thr 155160 165 GCC ATT TAC ACC TTT GAG TCT CTG GTC AAG ATT CTG GCT CGA GCT 540Ala Ile Tyr Thr Phe Glu Ser Leu Val Lys Ile Leu Ala Arg Ala 170 175 180TTC TGC CTG CAC GCG TTC ACT TTC CTT CGG GAC CCA TGG AAC TGG 585 Phe CysLeu His Ala Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp 185 190 195 CTG GACTTT AGT GTG ATT ATC ATG GCA TAC ACA ACT GAA TTT GTG 630 Leu Asp Phe SerVal Ile Ile Met Ala Tyr Thr Thr Glu Phe Val 200 205 210 GAC CTG GGC AATGTC TCA GCC TTA CGC ACC TTC CGA GTC CTC CGG 675 Asp Leu Gly Asn Val SerAla Leu Arg Thr Phe Arg Val Leu Arg 215 220 225 GCC CTG AAA ACT ATA TCAGTC ATT TCA GGG CTG AAG ACC ATC GTG 720 Ala Leu Lys Thr Ile Ser Val IleSer Gly Leu Lys Thr Ile Val 230 235 240 GGG GCC CTG ATC CAG TCT GTG AAGAAG CTG GCT GAT GTG ATG GTC 765 Gly Ala Leu Ile Gln Ser Val Lys Lys LeuAla Asp Val Met Val 245 250 255 CTC ACA GTC TTC TGC CTC AGC GTC TTT GCCCTC ATC GGC CTG CAG 810 Leu Thr Val Phe Cys Leu Ser Val Phe Ala Leu IleGly Leu Gln 260 265 270 CTC TTC ATG GGC AAC CTA AGG CAC AAG TGT GTG CGCAAC TTC ACA 855 Leu Phe Met Gly Asn Leu Arg His Lys Cys Val Arg Asn PheThr 275 280 285 GCG CTC AAC GGC ACC AAC GGC TCC GTG GAG GCC GAC GGC TTGGTC 900 Ala Leu Asn Gly Thr Asn Gly Ser Val Glu Ala Asp Gly Leu Val 290295 300 TGG GAA TCC CTG GAC CTT TAC CTC AGT GAT CCA GAA AAT TAC CTG 945Trp Glu Ser Leu Asp Leu Tyr Leu Ser Asp Pro Glu Asn Tyr Leu 305 310 315CTC AAG AAC GGC ACC TCT GAT GTG TTA CTG TGT GGG AAC AGC TCT 990 Leu LysAsn Gly Thr Ser Asp Val Leu Leu Cys Gly Asn Ser Ser 320 325 330 GAC GCTGGG ACA TGT CCG GAG GGC TAC CGG TGC CTA AAG GCA GGC 1035 Asp Ala Gly ThrCys Pro Glu Gly Tyr Arg Cys Leu Lys Ala Gly 335 340 345 GAG AAC CCC GACCAC GGC TAC ACC AGC TTC GAT TCC TTT GCC TGG 1080 Glu Asn Pro Asp His GlyTyr Thr Ser Phe Asp Ser Phe Ala Trp 350 355 360 GCC TTT CTT GCA CTC TTCCGC CTG ATG ACG CAG GAC TGC TGG GAG 1125 Ala Phe Leu Ala Leu Phe Arg LeuMet Thr Gln Asp Cys Trp Glu 365 370 375 CGC CTC TAT CAG CAG ACC CTC AGGTCC GCA GGG AAG ATC TAC ATG 1170 Arg Leu Tyr Gln Gln Thr Leu Arg Ser AlaGly Lys Ile Tyr Met 380 385 390 ATC TTC TTC ATG CTT GTC ATC TTC CTG GGGTCC TTC TAC CTG GTG 1215 Ile Phe Phe Met Leu Val Ile Phe Leu Gly Ser PheTyr Leu Val 395 400 405 AAC CTG ATC CTG GCC GTG GTC GCA ATG GCC TAT GAGGAG CAA AAC 1260 Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu GlnAsn 410 415 420 CAA GCC ACC ATC GCT GAG ACC GAG GAG AAG GAA AAG CGC TTCCAG 1305 Gln Ala Thr Ile Ala Glu Thr Glu Glu Lys Glu Lys Arg Phe Gln 425430 435 GAG GCC ATG GAA ATG CTC AAG AAA GAA CAC GAG GCC CTC ACC ATC 1350Glu Ala Met Glu Met Leu Lys Lys Glu His Glu Ala Leu Thr Ile 440 445 450AGG GGT GTG GAT ACC GTG TCC CGT AGC TCC TTG GAG ATG TCC CCT 1395 Arg GlyVal Asp Thr Val Ser Arg Ser Ser Leu Glu Met Ser Pro 455 460 465 TTG GCCCCA GTA AAC AGC CAT GAG AGA AGA AGC AAG AGG AGA AAA 1440 Leu Ala Pro ValAsn Ser His Glu Arg Arg Ser Lys Arg Arg Lys 470 475 480 CGG ATG TCT TCAGGA ACT GAG GAG TGT GGG GAG GAC AGG CTC CCC 1485 Arg Met Ser Ser Gly ThrGlu Glu Cys Gly Glu Asp Arg Leu Pro 485 490 495 AAG TCT GAC TCA GAA GATGGT CCC AGA GCA ATG AAT CAT CTC AGC 1530 Lys Ser Asp Ser Glu Asp Gly ProArg Ala Met Asn His Leu Ser 500 505 510 CTC ACC CGT GGC CTC AGC AGG ACTTCT ATG AAG CCA CGT TCC AGC 1575 Leu Thr Arg Gly Leu Ser Arg Thr Ser MetLys Pro Arg Ser Ser 515 520 525 CGC GGG AGC ATT TTC ACC TTT CGC AGG CGAGAC CTG GGT TCT GAA 1620 Arg Gly Ser Ile Phe Thr Phe Arg Arg Arg Asp LeuGly Ser Glu 530 535 540 GCA GAT TTT GCA GAT GAT GAA AAC AGC ACA GCG CGGGAG AGC GAG 1665 Ala Asp Phe Ala Asp Asp Glu Asn Ser Thr Ala Arg Glu SerGlu 545 550 555 AGC CAC CAC ACA TCA CTG CTG GTG CCC TGG CCC CTG CGC CGGACC 1710 Ser His His Thr Ser Leu Leu Val Pro Trp Pro Leu Arg Arg Thr 560565 570 AGT GCC CAG GGA CAG CCC AGT CCC GGA ACC TCG GCT CCT GGC CAC 1755Ser Ala Gln Gly Gln Pro Ser Pro Gly Thr Ser Ala Pro Gly His 575 580 585GCC CTC CAT GGC AAA AAG AAC AGC ACT GTG GAC TGC AAT GGG GTG 1800 Ala LeuHis Gly Lys Lys Asn Ser Thr Val Asp Cys Asn Gly Val 590 595 600 GTC TCATTA CTG GGG GCA GGC GAC CCA GAG GCC ACA TCC CCA GGA 1845 Val Ser Leu LeuGly Ala Gly Asp Pro Glu Ala Thr Ser Pro Gly 605 610 615 AGC CAC CTC CTCCGC CCT GTG ATG CTA GAG CAC CCG CCA GAC ACG 1890 Ser His Leu Leu Arg ProVal Met Leu Glu His Pro Pro Asp Thr 620 625 630 ACC ACG CCA TCG GAG GAGCCA GGC GGC CCC CAG ATG CTG ACC TCC 1935 Thr Thr Pro Ser Glu Glu Pro GlyGly Pro Gln Met Leu Thr Ser 635 640 645 CAG GCT CCG TGT GTA GAT GGC TTCGAG GAG CCA GGA GCA CGG CAG 1980 Gln Ala Pro Cys Val Asp Gly Phe Glu GluPro Gly Ala Arg Gln 650 655 660 CGG GCC CTC AGC GCA GTC AGC GTC CTC ACAAGC GCA CTG GAA GAG 2025 Arg Ala Leu Ser Ala Val Ser Val Leu Thr Ser AlaLeu Glu Glu 665 670 675 TTA GAG GAG TCT CGC CAC AAG TGT CCA CCA TGC TGGAAC CGT CTC 2070 Leu Glu Glu Ser Arg His Lys Cys Pro Pro Cys Trp Asn ArgLeu 680 685 690 GCC CAG CGC TAC CTG ATC TGG GAG TGC TGC CCG CTG TGG ATGTCC 2115 Ala Gln Arg Tyr Leu Ile Trp Glu Cys Cys Pro Leu Trp Met Ser 695700 705 ATC AAG CAG GGA GTG AAG TTG GTG GTC ATG GAC CCG TTT ACT GAC 2160Ile Lys Gln Gly Val Lys Leu Val Val Met Asp Pro Phe Thr Asp 710 715 720CTC ACC ATC ACT ATG TGC ATC GTA CTC AAC ACA CTC TTC ATG GCG 2205 Leu ThrIle Thr Met Cys Ile Val Leu Asn Thr Leu Phe Met Ala 725 730 735 CTG GAGCAC TAC AAC ATG ACA AGT GAA TTC GAG GAG ATG CTG CAG 2250 Leu Glu His TyrAsn Met Thr Ser Glu Phe Glu Glu Met Leu Gln 740 745 750 GTC GGA AAC CTGGTC TTC ACA GGG ATT TTC ACA GCA GAG ATG ACC 2295 Val Gly Asn Leu Val PheThr Gly Ile Phe Thr Ala Glu Met Thr 755 760 765 TTC AAG ATC ATT GCC CTCGAC CCC TAC TAC TAC TTC CAA CAG GGC 2340 Phe Lys Ile Ile Ala Leu Asp ProTyr Tyr Tyr Phe Gln Gln Gly 770 775 780 TGG AAC ATC TTC GAC AGC ATC ATCGTC ATC CTT AGC CTC ATG GAG 2385 Trp Asn Ile Phe Asp Ser Ile Ile Val IleLeu Ser Leu Met Glu 785 790 795 CTG GGC CTG TCC CGC ATG AGC AAC TTG TCGGTG CTG CGC TCC TTC 2430 Leu Gly Leu Ser Arg Met Ser Asn Leu Ser Val LeuArg Ser Phe 800 805 810 CGC CTG CTG CGG GTC TTC AAG CTG GCC AAA TCA TGGCCC ACC CTG 2475 Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser Trp Pro ThrLeu 815 820 825 AAC ACA CTC ATC AAG ATC ATC GGG AAC TCA GTG GGG GCA CTGGGG 2520 Asn Thr Leu Ile Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly 830835 840 AAC CTG ACA CTG GTG CTA GCC ATC ATC GTG TTC ATC TTT GCT GTG 2565Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe Ile Phe Ala Val 845 850 855GTG GGC ATG CAG CTC TTT GGC AAG AAC TAC TCG GAG CTG AGG GAC 2610 Val GlyMet Gln Leu Phe Gly Lys Asn Tyr Ser Glu Leu Arg Asp 860 865 870 AGC GACTCA GGC CTG CTG CCT CGC TGG CAC ATG ATG GAC TTC TTT 2655 Ser Asp Ser GlyLeu Leu Pro Arg Trp His Met Met Asp Phe Phe 875 880 885 CAT GCC TTC CTAATC ATC TTC CGC ATC CTC TGT GGA GAG TGG ATC 2700 His Ala Phe Leu Ile IlePhe Arg Ile Leu Cys Gly Glu Trp Ile 890 895 900 GAG ACC ATG TGG GAC TGCATG GAG GTG TCG GGG CAG TCA TTA TGC 2745 Glu Thr Met Trp Asp Cys Met GluVal Ser Gly Gln Ser Leu Cys 905 910 915 CTG CTG GTC TTC TTG CTT GTT ATGGTC ATT GGC AAC CTT GTG GTC 2790 Leu Leu Val Phe Leu Leu Val Met Val IleGly Asn Leu Val Val 920 925 930 CTG AAT CTC TTC CTG GCC TTG CTG CTC AGCTCC TTC AGT GCA GAC 2835 Leu Asn Leu Phe Leu Ala Leu Leu Leu Ser Ser PheSer Ala Asp 935 940 945 AAC CTC ACA GCC CCT GAT GAG GAC AGA GAG ATG AACAAC CTC CAG 2880 Asn Leu Thr Ala Pro Asp Glu Asp Arg Glu Met Asn Asn LeuGln 950 955 960 CTG GCC CTG GCC CGC ATC CAG AGG GGC CTG CGC TTT GTC AAGCGG 2925 Leu Ala Leu Ala Arg Ile Gln Arg Gly Leu Arg Phe Val Lys Arg 965970 975 ACC ACC TGG GAT TTC TGC TGT GGT CTC CTG CGG CAC CGG CCT CAG 2970Thr Thr Trp Asp Phe Cys Cys Gly Leu Leu Arg His Arg Pro Gln 980 985 990AAG CCC GCA GCC CTT GCC GCC CAG GGC CAG CTG CCC AGC TGC ATT 3015 Lys ProAla Ala Leu Ala Ala Gln Gly Gln Leu Pro Ser Cys Ile 995 1000 1005 GCCACC CCC TAC TCC CCG CCA CCC CCA GAG ACG GAG AAG GTG CCT 3060 Ala Thr ProTyr Ser Pro Pro Pro Pro Glu Thr Glu Lys Val Pro 1010 1015 1020 CCC ACCCGC AAG GAA ACA CAG TTT GAG GAA GGC GAG CAA CCA GGC 3105 Pro Thr Arg LysGlu Thr Gln Phe Glu Glu Gly Glu Gln Pro Gly 1025 1030 1035 CAG GGC ACCCCC GGG GAT CCA GAC GCC GTG TGT GTG CCC ATC GCT 3150 Gln Gly Thr Pro GlyAsp Pro Glu Pro Val Cys Val Pro Ile Ala 1040 1045 1050 GTG GCC GAG TCAGAC ACA GAT GAC CAA GAA GAG GAT GAG GAG AAC 3195 Val Ala Glu Ser Asp ThrAsp Asp Gln Glu Glu Asp Glu Glu Asn 1055 1060 1065 AGC CTG GGC ACG GAGGAG GAG TCC AGC AAG CAG CAG GAA TCC CAG 3240 Ser Leu Gly Thr Glu Glu GluSer Ser Lys Gln Gln Glu Ser Gln 1070 1075 1080 CCT GTG TCC GGC TGG CCCAGA GGC CCT CCG GAT TCC AGG ACC TGG 3285 Pro Val Ser Gly Trp Pro Arg GlyPro Pro Asp Ser Arg Thr Trp 1085 1090 1095 AGC CAG GTG TCA GCG ACT GCCTCC TCT GAG GCC GAG GCC AGT GCA 3330 Ser Gln Val Ser Ala Thr Ala Ser SerGlu Ala Glu Ala Ser Ala 1100 1105 1110 TCT CAG GCC GAC TGG CGG CAG CAGTGG AAA GCG GAA CCC CAG GCC 3375 Ser Gln Ala Asp Trp Arg Gln Gln Trp LysAla Glu Pro Gln Ala 1115 1120 1125 CCA GGG TGC GGT GAG ACC CCA GAG GACAGT TGC TCC GAG GGC AGC 3420 Pro Gly Cys Gly Glu Thr Pro Glu Asp Ser CysSer Glu Gly Ser 1130 1135 1140 ACA GCA GAC ATG ACC AAC ACC GCT GAG CTCCTG GAG CAG ATC CCT 3465 Thr Ala Asp Met Thr Asn Thr Ala Glu Leu Leu GluGln Ile Pro 1145 1150 1155 GAC CTC GGC CAG GAT GTC AAG GAC CCA GAG GACTGC TTC ACT GAA 3510 Asp Leu Gly Gln Asp Val Lys Asp Pro Glu Asp Cys PheThr Glu 1160 1165 1170 GGC TGT GTC CGG CGC TGT CCC TGC TGT GCG GTG GACACC ACA CAG 3555 Gly Cys Val Arg Arg Cys Pro Cys Cys Ala Val Asp Thr ThrGln 1175 1180 1185 GCC CCA GGG AAG GTC TGG TGG CGG TTG CGC AAG ACC TGCTAC CAC 3600 Ala Pro Gly Lys Val Trp Trp Arg Leu Arg Lys Thr Cys Tyr His1190 1195 1200 ATC GTG GAG CAC AGC TGG TTC GAG ACA TTC ATC ATC TTC ATGATC 3645 Ile Val Glu His Ser Trp Phe Glu Thr Phe Ile Ile Phe Met Ile1205 1210 1215 CTA CTC AGC AGT GGA GCG CTG GCC TTC GAG GAC ATC TAC CTAGAG 3690 Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr Leu Glu1220 1225 1230 GAG CGG AAG ACC ATC AAG GTT CTG CTT GAG TAT GCC GAC AAGATG 3735 Glu Arg Lys Thr Ile Lys Val Leu Leu Glu Tyr Ala Asp Lys Met1235 1240 1245 TTC ACA TAT GTC TTC GTG CTG GAG ATG CTG CTC AAG TGG GTGGCC 3780 Phe Thr Tyr Val Phe Val Leu Glu Met Leu Leu Lys Trp Val Ala1250 1255 1260 TAC GGC TTC AAG AAG TAC TTC ACC AAT GCC TGG TGC TGG CTCGAC 3825 Tyr Gly Phe Lys Lys Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp1265 1270 1275 TTC CTC ATC GTA GAC GTC TCT CTG GTC AGC CTG GTG GCC AACACC 3870 Phe Leu Ile Val Asp Val Ser Leu Val Ser Leu Val Ala Asn Thr1280 1285 1290 CTG GGC TTT GCC GAG ATG GGC CCC ATC AAG TCA CTG CGG ACGCTG 3915 Leu Gly Phe Ala Glu Met Gly Pro Ile Lys Ser Leu Arg Thr Leu1295 1300 1305 CGT GCA CTC CGT CCT CTG AGA GCT CTG TCA CGA TTT GAG GGCATG 3960 Arg Ala Leu Arg Pro Leu Arg Ala Leu Ser Arg Phe Glu Gly Met1310 1315 1320 AGG GTG GTG GTC AAT GCC CTG GTG GGC GCC ATC CCG TCC ATCATG 4005 Arg Val Val Val Asn Ala Leu Val Gly Ala Ile Pro Ser Ile Met1325 1330 1335 AAC GTC CTC CTC GTC TGC CTC ATC TTC TGG CTC ATC TTC AGCATC 4050 Asn Val Leu Leu Val Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile1340 1345 1350 ATG GGC GTG AAC CTC TTT GCG GGG AAG TTT GGG AGG TGC ATCAAC 4095 Met Gly Val Asn Leu Phe Ala Gly Lys Phe Gly Arg Cys Ile Asn1355 1360 1365 CAG ACA GAG GGA GAC TTG CCT TTG AAC TAC ACC ATC GTG AACAAC 4140 Gln Thr Glu Gly Asp Leu Pro Leu Asn Tyr Thr Ile Val Asn Asn1370 1375 1380 AAG AGC CAG TGT GAG TCC TTG AAC TTG ACC GGA GAA TTG TACTGG 4185 Lys Ser Gln Cys Glu Ser Leu Asn Leu Thr Gly Glu Leu Tyr Trp1385 1390 1395 ACC AAG GTG AAA GTC AAC TTT GAC AAC GTG GGG GCC GGG TACCTG 4230 Thr Lys Val Lys Val Asn Phe Asp Asn Val Gly Ala Gly Tyr Leu1400 1405 1410 GCC CTT CTG CAG GTG GCA ACA TTT AAA GGC TGG ATG GAC ATTATG 4275 Ala Leu Leu Gln Val Ala Thr Phe Lys Gly Trp Met Asp Ile Met1415 1420 1425 TAT GCA GCT GTG GAC TCC AGG GGG TAT GAA GAG CAG CCT CAGTGG 4320 Tyr Ala Ala Val Asp Ser Arg Gly Tyr Glu Glu Gln Pro Gln Trp1430 1435 1440 GAA TAC AAC CTC TAC ATG TAC ATC TAT TTT GTC ATT TTC ATCATC 4365 Glu Tyr Asn Leu Tyr Met Tyr Ile Tyr Phe Val Ile Phe Ile Ile1445 1450 1455 TTT GGG TCT TTC TTC ACC CTG AAC CTC TTT ATT GGT GTC ATCATT 4410 Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe Ile Gly Val Ile Ile1460 1465 1470 GAC AAC TTC AAC CAA CAG AAG AAA AAG TTA GGG GGC CAG GACATC 4455 Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu Gly Gly Gln Asp Ile1475 1480 1485 TTC ATG ACA GAG GAG CAG AAG AAG TAC TAC AAT GCC ATG AAGAAG 4500 Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys1490 1495 1500 CTG GGC TCC AAG AAG CCC CAG AAG CCC ATC CCA CGG CCC CTGAAC 4545 Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro Arg Pro Leu Asn1505 1510 1515 AAG TAC CAG GGC TTC ATA TTC GAC ATT GTG ACC AAG CAG GCCTTT 4590 Lys Tyr Gln Gly Phe Ile Phe Asp Ile Val Thr Lys Gln Ala Phe1520 1525 1530 GAC GTC ACC ATC ATG TTT CTG ATC TGC TTG AAT ATG GTG ACCATG 4635 Asp Val Thr Ile Met Phe Leu Ile Cys Leu Asn Met Val Thr Met1535 1540 1545 ATG GTG GAG ACA GAT GAC CAA AGT CCT GAG AAA ATC AAC ATCTTG 4680 Met Val Glu Thr Asp Asp Gln Ser Pro Glu Lys Ile Asn Ile Leu1550 1555 1560 GCC AAG ATC AAC CTG CTC TTT GTG GCC ATC TTC ACA GGC GAGTGT 4725 Ala Lys Ile Asn Leu Leu Phe Val Ala Ile Phe Thr Gly Glu Cys1565 1570 1575 ATT GTC AAG CTG GCT GCC CTG CGC CAC TAC TAC TTC ACC AACAGC 4770 Ile Val Lys Leu Ala Ala Leu Arg His Tyr Tyr Phe Thr Asn Ser1580 1585 1590 TGG AAT ATC TTC GAC TTC GTG GTT GTC ATC CTC TCC ATC GTGGGC 4815 Trp Asn Ile Phe Asp Phe Val Val Val Ile Leu Ser Ile Val Gly1595 1600 1605 ACT GTG CTC TCG GAC ATC ATC CAG AAG TAC TTC TTC TCC CCGACG 4860 Thr Val Leu Ser Asp Ile Ile Gln Lys Tyr Phe Phe Ser Pro Thr1610 1615 1620 CTC TTC CGA GTC ATC CGC CTG GCC CGA ATA GGC CGC ATC CTCAGA 4905 Leu Phe Arg Val Ile Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg1625 1630 1635 CTG ATC CGA GGG GCC AAG GGG ATC CGC ACG CTG CTC TTT GCCCTC 4950 Leu Ile Arg Gly Ala Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu1640 1645 1650 ATG ATG TCC CTG CCT GCC CTC TTC AAC ATC GGG CTG CTG CTCTTC 4995 Met Met Ser Leu Pro Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe1655 1660 1665 CTC GTC ATG TTC ATC TAC TCC ATC TTT GGC ATG GCC AAC TTCGCT 5040 Leu Val Met Phe Ile Tyr Ser Ile Phe Gly Met Ala Asn Phe Ala1670 1675 1680 TAT GTC AAG TGG GAG GCT GGC ATC GAC GAC ATG TTC AAC TTCCAG 5085 Tyr Val Lys Trp Glu Ala Gly Ile Asp Asp Met Phe Asn Phe Gln1685 1690 1695 ACC TTC GCC AAC AGC ATG CTG TGC CTC TTC CAG ATC ACC ACGTCG 5130 Thr Phe Ala Asn Ser Met Leu Cys Leu Phe Gln Ile Thr Thr Ser1700 1705 1710 GCC GGC TGG GAT GGC CTC CTC AGC CCC ATC CTC AAC ACT GGGCCG 5175 Ala Gly Trp Asp Gly Leu Leu Ser Pro Ile Leu Asn Thr Gly Pro1715 1720 1725 CCC TAC TGC GAC CCC ACT CTG CCC AAC AGC AAT GGC TCT CGGGGG 5220 Pro Tyr Cys Asp Pro Thr Leu Pro Asn Ser Asn Gly Ser Arg Gly1730 1735 1740 GAC TGC GGG AGC CCA GCC GTG GGC ATC CTC TTC TTC ACC ACCTAC 5265 Asp Cys Gly Ser Pro Ala Val Gly Ile Leu Phe Phe Thr Thr Tyr1745 1750 1755 ATC ATC ATC TCC TTC CTC ATC GTG GTC AAC ATG TAC ATT GCCATC 5310 Ile Ile Ile Ser Phe Leu Ile Val Val Asn Met Tyr Ile Ala Ile1760 1765 1770 ATC CTG GAG AAC TTC AGC GTG GCC ACG GAG GAG AGC ACC GAGCCC 5355 Ile Leu Glu Asn Phe Ser Val Ala Thr Glu Glu Ser Thr Glu Pro1775 1780 1785 CTG AGT GAG GAC GAC TTC GAT ATG TTC TAT GAG ATC TGG GAGAAA 5400 Leu Ser Glu Asp Asp Phe Asp Met Phe Tyr Glu Ile Trp Glu Lys1790 1795 1800 TTT GAC CCA GAG GCC ACT CAG TTT ATT GAG TAT TCG GTC CTGTCT 5445 Phe Asp Pro Glu Ala Thr Gln Phe Ile Glu Tyr Ser Val Leu Ser1805 1810 1815 GAC TTT GCC GAC GCC CTG TCT GAG CCA CTC CGT ATC GCC AAGCCC 5490 Asp Phe Ala Asp Ala Leu Ser Glu Pro Leu Ile Arg Ala Lys Pro1820 1825 1830 AAC CAG ATA AGC CTC ATC AAC ATG GAC CTG CCC ATG GTG AGTGGG 5535 Asn Gln Ile Ser Leu Ile Asn Met Asp Leu Pro Met Val Ser Gly1835 1840 1845 GAC CGC ATC CAT TGC ATG GAC ATT CTC TTT GCC TTC ACC AAAAGG 5580 Asp Arg Ile His Cys Met Asp Ile Leu Phe Ala Phe Thr Lys Arg1850 1855 1860 GTC CTG GGG GAG TCT GGG GAG ATG GAC GCC CTG AAG ATC CAGATG 5625 Val Leu Gly Glu Ser Gly Glu Met Asp Ala Leu Lys Ile Gln Met1865 1870 1875 GAG GAG AAG TTC ATG GCA GCC AAC CCA TCC AAG ATC TCC TACGAG 5670 Glu Glu Lys Phe Met Ala Ala Asn Pro Ser Lys Ile Ser Tyr Glu1880 1885 1890 CCC ATC ACC ACC ACA CTC CGG CGC AAG CAC GAA GAG GTG TCGGCC 5715 Pro Ile Thr Thr Thr Leu Arg Arg Lys His Glu Glu Val Ser Ala1895 1900 1905 ATG GTT ATC CAG AGA GCC TTC CGC AGG CAC CTG CTG CAA CGCTCT 5760 Met Val Ile Gln Arg Ala Phe Arg Arg His Leu Leu Gln Arg Ser1910 1915 1920 TTG AAG CAT GCC TCC TTC CTC TTC CGT CAG CAG GCG GGC AGCGGC 5805 Leu Lys His Ala Ser Phe Leu Phe Arg Gln Gln Ala Gly Ser Gly1925 1930 1935 CTC TCC GAA GAG GAT GCC CCT GAG CGA GAG GGC CTC ATC GCCTAC 5850 Leu Ser Glu Glu Asp Ala Pro Glu Arg Glu Gly Leu Ile Ala Tyr1940 1945 1950 GTG ATG AGT GAG AAC TTC TCC CGA CCC CTT GGC CCA CCC TCCAGC 5895 Val Met Ser Glu Asn Phe Ser Arg Pro Leu Gly Pro Pro Ser Ser1955 1960 1965 TCC TCC ATC TCC TCC ACT TCC TTC CCA CCC TCC TAT GAC AGTGTC 5940 Ser Ser Ile Ser Ser Thr Ser Phe Pro Pro Ser Tyr Asp Ser Val1970 1975 1980 ACT AGA GCC ACC AGC GAT AAC CTC CAG GTG CGG GGG TCT GACTAC 5985 Thr Arg Ala Thr Ser Asp Asn Leu Gln Val Arg Gly Ser Asp Tyr1985 1990 1995 AGC CAC AGT GAA GAT CTC GCC GAC TTC CCC CCT TCT CCG GACAGG 6030 Ser His Ser Glu Asp Leu Ala Asp Phe Pro Pro Ser Pro Asp Arg2000 2005 2010 GAC CGT GAG TCC ATC GTG 6048 Asp Arg Glu Ser Ile Val 20152016 amino acids amino acid single unknown 2 Met Ala Asn Phe Leu Leu ProArg Gly Thr Ser Ser Phe Arg Arg 1 5 10 15 Phe Thr Arg Glu Ser Leu AlaAla Ile Glu Lys Arg Met Ala Glu 20 25 30 Lys Gln Ala Arg Gly Ser Thr ThrLeu Gln Glu Ser Arg Glu Gly 35 40 45 Leu Pro Glu Glu Glu Ala Pro Arg ProGln Leu Asp Leu Gln Ala 50 55 60 Ser Lys Lys Leu Pro Asp Leu Tyr Gly AsnPro Pro Gln Glu Leu 65 70 75 Ile Gly Glu Pro Leu Glu Asp Leu Asp Pro PheTyr Ser Thr Gln 80 85 90 Lys Thr Phe Ile Val Leu Asn Lys Gly Lys Thr IlePhe Arg Phe 95 100 105 Ser Ala Thr Asn Ala Leu Tyr Val Leu Ser Pro PheHis Pro Val 110 115 120 Arg Arg Ala Ala Val Lys Ile Leu Val His Ser LeuPhe Asn Met 125 130 135 Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val PheMet Ala Gln 140 145 150 His Asp Pro Pro Pro Trp Thr Lys Tyr Val Glu TyrThr Phe Thr 155 160 165 Ala Ile Tyr Thr Phe Glu Ser Leu Val Lys Ile LeuAla Arg Ala 170 175 180 Phe Cys Leu His Ala Phe Thr Phe Leu Arg Asp ProTrp Asn Trp 185 190 195 Leu Asp Phe Ser Val Ile Ile Met Ala Tyr Thr ThrGlu Phe Val 200 205 210 Asp Leu Gly Asn Val Ser Ala Leu Arg Thr Phe ArgVal Leu Arg 215 220 225 Ala Leu Lys Thr Ile Ser Val Ile Ser Gly Leu LysThr Ile Val 230 235 240 Gly Ala Leu Ile Gln Ser Val Lys Lys Leu Ala AspVal Met Val 245 250 255 Leu Thr Val Phe Cys Leu Ser Val Phe Ala Leu IleGly Leu Gln 260 265 270 Leu Phe Met Gly Asn Leu Arg His Lys Cys Val ArgAsn Phe Thr 275 280 285 Ala Leu Asn Gly Thr Asn Gly Ser Val Glu Ala AspGly Leu Val 290 295 300 Trp Glu Ser Leu Asp Leu Tyr Leu Ser Asp Pro GluAsn Tyr Leu 305 310 315 Leu Lys Asn Gly Thr Ser Asp Val Leu Leu Cys GlyAsn Ser Ser 320 325 330 Asp Ala Gly Thr Cys Pro Glu Gly Tyr Arg Cys LeuLys Ala Gly 335 340 345 Glu Asn Pro Asp His Gly Tyr Thr Ser Phe Asp SerPhe Ala Trp 350 355 360 Ala Phe Leu Ala Leu Phe Arg Leu Met Thr Gln AspCys Trp Glu 365 370 375 Arg Leu Tyr Gln Gln Thr Leu Arg Ser Ala Gly LysIle Tyr Met 380 385 390 Ile Phe Phe Met Leu Val Ile Phe Leu Gly Ser PheTyr Leu Val 395 400 405 Asn Leu Ile Leu Ala Val Val Ala Met Ala Tyr GluGlu Gln Asn 410 415 420 Gln Ala Thr Ile Ala Glu Thr Glu Glu Lys Glu LysArg Phe Gln 425 430 435 Glu Ala Met Glu Met Leu Lys Lys Glu His Glu AlaLeu Thr Ile 440 445 450 Arg Gly Val Asp Thr Val Ser Arg Ser Ser Leu GluMet Ser Pro 455 460 465 Leu Ala Pro Val Asn Ser His Glu Arg Arg Ser LysArg Arg Lys 470 475 480 Arg Met Ser Ser Gly Thr Glu Glu Cys Gly Glu AspArg Leu Pro 485 490 495 Lys Ser Asp Ser Glu Asp Gly Pro Arg Ala Met AsnHis Leu Ser 500 505 510 Leu Thr Arg Gly Leu Ser Arg Thr Ser Met Lys ProArg Ser Ser 515 520 525 Arg Gly Ser Ile Phe Thr Phe Arg Arg Arg Asp LeuGly Ser Glu 530 535 540 Ala Asp Phe Ala Asp Asp Glu Asn Ser Thr Ala ArgGlu Ser Glu 545 550 555 Ser His His Thr Ser Leu Leu Val Pro Trp Pro LeuArg Arg Thr 560 565 570 Ser Ala Gln Gly Gln Pro Ser Pro Gly Thr Ser AlaPro Gly His 575 580 585 Ala Leu His Gly Lys Lys Asn Ser Thr Val Asp CysAsn Gly Val 590 595 600 Val Ser Leu Leu Gly Ala Gly Asp Pro Glu Ala ThrSer Pro Gly 605 610 615 Ser His Leu Leu Arg Pro Val Met Leu Glu His ProPro Asp Thr 620 625 630 Thr Thr Pro Ser Glu Glu Pro Gly Gly Pro Gln MetLeu Thr Ser 635 640 645 Gln Ala Pro Cys Val Asp Gly Phe Glu Glu Pro GlyAla Arg Gln 650 655 660 Arg Ala Leu Ser Ala Val Ser Val Leu Thr Ser AlaLeu Glu Glu 665 670 675 Leu Glu Glu Ser Arg His Lys Cys Pro Pro Cys TrpAsn Arg Leu 680 685 690 Ala Gln Arg Tyr Leu Ile Trp Glu Cys Cys Pro LeuTrp Met Ser 695 700 705 Ile Lys Gln Gly Val Lys Leu Val Val Met Asp ProPhe Thr Asp 710 715 720 Leu Thr Ile Thr Met Cys Ile Val Leu Asn Thr LeuPhe Met Ala 725 730 735 Leu Glu His Tyr Asn Met Thr Ser Glu Phe Glu GluMet Leu Gln 740 745 750 Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr AlaGlu Met Thr 755 760 765 Phe Lys Ile Ile Ala Leu Asp Pro Tyr Tyr Tyr PheGln Gln Gly 770 775 780 Trp Asn Ile Phe Asp Ser Ile Ile Val Ile Leu SerLeu Met Glu 785 790 795 Leu Gly Leu Ser Arg Met Ser Asn Leu Ser Val LeuArg Ser Phe 800 805 810 Arg Leu Leu Arg Val Phe Lys Leu Ala Lys Ser TrpPro Thr Leu 815 820 825 Asn Thr Leu Ile Lys Ile Ile Gly Asn Ser Val GlyAla Leu Gly 830 835 840 Asn Leu Thr Leu Val Leu Ala Ile Ile Val Phe IlePhe Ala Val 845 850 855 Val Gly Met Gln Leu Phe Gly Lys Asn Tyr Ser GluLeu Arg Asp 860 865 870 Ser Asp Ser Gly Leu Leu Pro Arg Trp His Met MetAsp Phe Phe 875 880 885 His Ala Phe Leu Ile Ile Phe Arg Ile Leu Cys GlyGlu Trp Ile 890 895 900 Glu Thr Met Trp Asp Cys Met Glu Val Ser Gly GlnSer Leu Cys 905 910 915 Leu Leu Val Phe Leu Leu Val Met Val Ile Gly AsnLeu Val Val 920 925 930 Leu Asn Leu Phe Leu Ala Leu Leu Leu Ser Ser PheSer Ala Asp 935 940 945 Asn Leu Thr Ala Pro Asp Glu Asp Arg Glu Met AsnAsn Leu Gln 950 955 960 Leu Ala Leu Ala Arg Ile Gln Arg Gly Leu Arg PheVal Lys Arg 965 970 975 Thr Thr Trp Asp Phe Cys Cys Gly Leu Leu Arg HisArg Pro Gln 980 985 990 Lys Pro Ala Ala Leu Ala Ala Gln Gly Gln Leu ProSer Cys Ile 995 1000 1005 Ala Thr Pro Tyr Ser Pro Pro Pro Pro Glu ThrGlu Lys Val Pro 1010 1015 1020 Pro Thr Arg Lys Glu Thr Gln Phe Glu GluGly Glu Gln Pro Gly 1025 1030 1035 Gln Gly Thr Pro Gly Asp Pro Glu ProVal Cys Val Pro Ile Ala 1040 1045 1050 Val Ala Glu Ser Asp Thr Asp AspGln Glu Glu Asp Glu Glu Asn 1055 1060 1065 Ser Leu Gly Thr Glu Glu GluSer Ser Lys Gln Gln Glu Ser Gln 1070 1075 1080 Pro Val Ser Gly Trp ProArg Gly Pro Pro Asp Ser Arg Thr Trp 1085 1090 1095 Ser Gln Val Ser AlaThr Ala Ser Ser Glu Ala Glu Ala Ser Ala 1100 1105 1110 Ser Gln Ala AspTrp Arg Gln Gln Trp Lys Ala Glu Pro Gln Ala 1115 1120 1125 Pro Gly CysGly Glu Thr Pro Glu Asp Ser Cys Ser Glu Gly Ser 1130 1135 1140 Thr AlaAsp Met Thr Asn Thr Ala Glu Leu Leu Glu Gln Ile Pro 1145 1150 1155 AspLeu Gly Gln Asp Val Lys Asp Pro Glu Asp Cys Phe Thr Glu 1160 1165 1170Gly Cys Val Arg Arg Cys Pro Cys Cys Ala Val Asp Thr Thr Gln 1175 11801185 Ala Pro Gly Lys Val Trp Trp Arg Leu Arg Lys Thr Cys Tyr His 11901195 1200 Ile Val Glu His Ser Trp Phe Glu Thr Phe Ile Ile Phe Met Ile1205 1210 1215 Leu Leu Ser Ser Gly Ala Leu Ala Phe Glu Asp Ile Tyr LeuGlu 1220 1225 1230 Glu Arg Lys Thr Ile Lys Val Leu Leu Glu Tyr Ala AspLys Met 1235 1240 1245 Phe Thr Tyr Val Phe Val Leu Glu Met Leu Leu LysTrp Val Ala 1250 1255 1260 Tyr Gly Phe Lys Lys Tyr Phe Thr Asn Ala TrpCys Trp Leu Asp 1265 1270 1275 Phe Leu Ile Val Asp Val Ser Leu Val SerLeu Val Ala Asn Thr 1280 1285 1290 Leu Gly Phe Ala Glu Met Gly Pro IleLys Ser Leu Arg Thr Leu 1295 1300 1305 Arg Ala Leu Arg Pro Leu Arg AlaLeu Ser Arg Phe Glu Gly Met 1310 1315 1320 Arg Val Val Val Asn Ala LeuVal Gly Ala Ile Pro Ser Ile Met 1325 1330 1335 Asn Val Leu Leu Val CysLeu Ile Phe Trp Leu Ile Phe Ser Ile 1340 1345 1350 Met Gly Val Asn LeuPhe Ala Gly Lys Phe Gly Arg Cys Ile Asn 1355 1360 1365 Gln Thr Glu GlyAsp Leu Pro Leu Asn Tyr Thr Ile Val Asn Asn 1370 1375 1380 Lys Ser GlnCys Glu Ser Leu Asn Leu Thr Gly Glu Leu Tyr Trp 1385 1390 1395 Thr LysVal Lys Val Asn Phe Asp Asn Val Gly Ala Gly Tyr Leu 1400 1405 1410 AlaLeu Leu Gln Val Ala Thr Phe Lys Gly Trp Met Asp Ile Met 1415 1420 1425Tyr Ala Ala Val Asp Ser Arg Gly Tyr Glu Glu Gln Pro Gln Trp 1430 14351440 Glu Tyr Asn Leu Tyr Met Tyr Ile Tyr Phe Val Ile Phe Ile Ile 14451450 1455 Phe Gly Ser Phe Phe Thr Leu Asn Leu Phe Ile Gly Val Ile Ile1460 1465 1470 Asp Asn Phe Asn Gln Gln Lys Lys Lys Leu Gly Gly Gln AspIle 1475 1480 1485 Phe Met Thr Glu Glu Gln Lys Lys Tyr Tyr Asn Ala MetLys Lys 1490 1495 1500 Leu Gly Ser Lys Lys Pro Gln Lys Pro Ile Pro ArgPro Leu Asn 1505 1510 1515 Lys Tyr Gln Gly Phe Ile Phe Asp Ile Val ThrLys Gln Ala Phe 1520 1525 1530 Asp Val Thr Ile Met Phe Leu Ile Cys LeuAsn Met Val Thr Met 1535 1540 1545 Met Val Glu Thr Asp Asp Gln Ser ProGlu Lys Ile Asn Ile Leu 1550 1555 1560 Ala Lys Ile Asn Leu Leu Phe ValAla Ile Phe Thr Gly Glu Cys 1565 1570 1575 Ile Val Lys Leu Ala Ala LeuArg His Tyr Tyr Phe Thr Asn Ser 1580 1585 1590 Trp Asn Ile Phe Asp PheVal Val Val Ile Leu Ser Ile Val Gly 1595 1600 1605 Thr Val Leu Ser AspIle Ile Gln Lys Tyr Phe Phe Ser Pro Thr 1610 1615 1620 Leu Phe Arg ValIle Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg 1625 1630 1635 Leu Ile ArgGly Ala Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu 1640 1645 1650 Met MetSer Leu Pro Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe 1655 1660 1665 LeuVal Met Phe Ile Tyr Ser Ile Phe Gly Met Ala Asn Phe Ala 1670 1675 1680Tyr Val Lys Trp Glu Ala Gly Ile Asp Asp Met Phe Asn Phe Gln 1685 16901695 Thr Phe Ala Asn Ser Met Leu Cys Leu Phe Gln Ile Thr Thr Ser 17001705 1710 Ala Gly Trp Asp Gly Leu Leu Ser Pro Ile Leu Asn Thr Gly Pro1715 1720 1725 Pro Tyr Cys Asp Pro Thr Leu Pro Asn Ser Asn Gly Ser ArgGly 1730 1735 1740 Asp Cys Gly Ser Pro Ala Val Gly Ile Leu Phe Phe ThrThr Tyr 1745 1750 1755 Ile Ile Ile Ser Phe Leu Ile Val Val Asn Met TyrIle Ala Ile 1760 1765 1770 Ile Leu Glu Asn Phe Ser Val Ala Thr Glu GluSer Thr Glu Pro 1775 1780 1785 Leu Ser Glu Asp Asp Phe Asp Met Phe TyrGlu Ile Trp Glu Lys 1790 1795 1800 Phe Asp Pro Glu Ala Thr Gln Phe IleGlu Tyr Ser Val Leu Ser 1805 1810 1815 Asp Phe Ala Asp Ala Leu Ser GluPro Leu Ile Arg Ala Lys Pro 1820 1825 1830 Asn Gln Ile Ser Leu Ile AsnMet Asp Leu Pro Met Val Ser Gly 1835 1840 1845 Asp Arg Ile His Cys MetAsp Ile Leu Phe Ala Phe Thr Lys Arg 1850 1855 1860 Val Leu Gly Glu SerGly Glu Met Asp Ala Leu Lys Ile Gln Met 1865 1870 1875 Glu Glu Lys PheMet Ala Ala Asn Pro Ser Lys Ile Ser Tyr Glu 1880 1885 1890 Pro Ile ThrThr Thr Leu Arg Arg Lys His Glu Glu Val Ser Ala 1895 1900 1905 Met ValIle Gln Arg Ala Phe Arg Arg His Leu Leu Gln Arg Ser 1910 1915 1920 LeuLys His Ala Ser Phe Leu Phe Arg Gln Gln Ala Gly Ser Gly 1925 1930 1935Leu Ser Glu Glu Asp Ala Pro Glu Arg Glu Gly Leu Ile Ala Tyr 1940 19451950 Val Met Ser Glu Asn Phe Ser Arg Pro Leu Gly Pro Pro Ser Ser 19551960 1965 Ser Ser Ile Ser Ser Thr Ser Phe Pro Pro Ser Tyr Asp Ser Val1970 1975 1980 Thr Arg Ala Thr Ser Asp Asn Leu Gln Val Arg Gly Ser AspTyr 1985 1990 1995 Ser His Ser Glu Asp Leu Ala Asp Phe Pro Pro Ser ProAsp Arg 2000 2005 2010 Asp Arg Glu Ser Ile Val 2015 24 bases nucleicacid single linear 3 ATGGCAAACT TCCTATTACC TCGG 24 24 bases nucleic acidsingle linear 4 CACGATGGAC TCACGGTCCC TGTC 24 3069 bases nucleic aciddouble linear 5 ATG GGG AAG GGG GTT GGA CGT GAT AAG TAT GAG CCT GCA GCTGTT 45 Met Gly Lys Gly Val Gly Arg Asp Lys Tyr Glu Pro Ala Ala Val 1 510 15 TCA GAA CAA GGT GAT AAA AAG GGC AAA AAG GGC AAA AAA GAC AGG 90 SerGlu Gln Glu Asp Lys Lys Glu Lys Lys Glu Lys Lys Asp Arg 20 25 30 GAC ATGGAT GAA CTG AAG AAA GAA GTT TCT ATG GAT GAT CAT AAA 135 Asp Met Asp GluLeu Lys Lys Glu Val Ser Met Asp Asp His Lys 35 40 45 CTT AGC CTT GAT GAACTT CAT CGT AAA TAT GGA ACA GAC TTG AGC 180 Leu Ser Leu Asp Glu Leu HisArg Lys Tyr Gly Thr Asp Leu Ser 50 55 60 CGG GGA TTA ACA TCT GCT CGT GCAGCT GAG ATC CTG GCG CGA GAT 225 Arg Gly Leu Thr Ser Ala Arg Ala Ala GluIle Leu Ala Arg Asp 65 70 75 GGT CCC AAC GCC CTC ACT CCC CCT CCC ACT ACTCCT GAA TGG ATC 270 Gly Pro Asn Ala Leu Thr Pro Pro Pro Thr Thr Pro GluTrp Ile 80 85 90 AAG TTT TGT CGG CAG CTC TTT GGG GGG TTC TCA ATG TTA CTGTGG 315 Lys Phe Cys Arg Gln Leu Phe Gly Gly Phe Ser Met Leu Leu Trp 95100 105 ATT GGA GCG ATT CTT TGT TTC TTG GCT TAT AGC ATC CAA GCT GCT 360Ile Gly Ala Ile Leu Cys Phe Leu Ala Tyr Ser Ile Gln Ala Ala 110 115 120ACA GAA GAG GAA CCT CAA AAC GAT AAT CTG TAC CTG GGT GTG GTG 405 Thr GluGlu Glu Pro Gln Asn Asp Asn Leu Tyr Leu Gly Val Val 125 130 135 CTA TCAGCC GTT GTA ATC ATA ACT GGT TGC TTC TCC TAC TAT CAA 450 Leu Ser Ala ValVal Ile Ile Thr Gly Cys Phe Ser Tyr Tyr Gln 140 145 150 GAA GCT AAA AGTTCA AAG ATC ATG GAA TCC TTC AAA AAC ATG GTC 495 Glu Ala Lys Ser Ser LysIle Met Glu Ser Phe Lys Asn Met Val 155 160 165 CCT CAG CAA GCC CTT GTGATT CGA AAT GGT GAG AAA ATG AGC ATA 540 Pro Gln Gln Ala Leu Val Ile ArgAsn Gly Glu Lys Met Ser Ile 170 175 180 AAT GCG GAG GAA GTT GTG GTT GGGGAT CTG GTG GAA GTA AAA GGA 585 Asn Ala Glu Glu Val Val Val Gly Asp LeuVal Glu Val Lys Gly 185 190 195 GGA GAC CGA ATT CCT GCT GAC CTC AGA ATCATA TCT GCA AAT GGC 630 Gly Asp Arg Ile Pro Ala Asp Leu Arg Ile Ile SerAla Asn Gly 200 205 210 TGC AAG GTG GAT AAC TCC TCG CTC ACT GGT GAA TCAGAA CCC CAG 675 Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu Ser Glu ProGln 215 220 225 ACT AGG TCT CCA GAT TTC ACA AAT GAA AAC CCC CTG GAG ACGAGG 720 Thr Arg Ser Pro Asp Phe Thr Asn Glu Asn Pro Leu Glu Thr Arg 230235 240 AAC ATT GCC TTC TTT TCA ACA AAT TGT GTT GAA GGC ACC GCA CGT 765Asn Ile Ala Phe Phe Ser Thr Asn Cys Val Glu Gly Thr Ala Arg 245 250 255GGT ATT GTT GTC TAC ACT GGG GAT CGC ACT GTG ATG GGA AGA ATT 810 Gly IleVal Val Tyr Thr Gly Asp Arg Thr Val Met Gly Arg Ile 260 265 270 GCC ACACTT GCT TCT GGG CTG GAA GGA GGC CAG ACC CCC ATT GCT 855 Ala Thr Leu AlaSer Gly Leu Glu Gly Gly Gln Thr Pro Ile Ala 275 280 285 GCA GAA ATT GAACAT TTT ATC CAC ATC ATC ACG GGT GTG GCT GTG 900 Ala Glu Ile Glu His PheIle His Ile Ile Thr Gly Val Ala Val 290 295 300 TTC CTG GGT GTG TCT TTCTTC ATC CTT TCT CTC ATC CTT GAG TAC 945 Phe Leu Gly Val Ser Phe Phe IleLeu Ser Leu Ile Leu Glu Tyr 305 310 315 ACC TGG CTT GAG GCT GTC ATC TTCCTC ATC GGT ATC ATC GTA GCC 990 Thr Trp Leu Glu Ala Val Ile Phe Leu IleGly Ile Ile Val Ala 320 325 330 AAT GTG CCG GAA GGT TTG CTG GCC ACT GTCACG GTC TGT CTG ACA 1035 Asn Val Pro Glu Gly Leu Leu Ala Thr Val Thr ValCys Leu Thr 335 340 345 CTT ACT GCC AAA CGC ATG GCA AGG AAA AAC TGC TTAGTG AAG AAC 1080 Leu Thr Ala Lys Arg Met Ala Arg Lys Asn Cys Leu Val LysAsn 350 355 360 TTA GAA GCT GTG GAG ACC TTG GGG TCC ACG TCC ACC ATC TGCTCT 1125 Leu Glu Ala Val Glu Thr Leu Gly Ser Thr Ser Thr Ile Cys Ser 365370 375 GAT AAA ACT GGA ACT CTG ACT CAG AAC CGG ATG ACA GTG GCC CAC 1170Asp Lys Thr Gly Thr Leu Thr Gln Asn Arg Met Thr Val Ala His 380 385 390ATG TGG TTT GAC AAT CAA ATC CAT GAA GCT GAT ACG ACA GAG AAT 1215 Met TrpPhe Asp Asn Gln Ile His Glu Ala Asp Thr Thr Glu Asn 395 400 405 CAG AGTGGT GTC TCT TTT GAC AAG ACT TCA GCT ACC TGG CTT GCT 1260 Gln Ser Gly ValSer Phe Asp Lys Thr Ser Ala Thr Trp Leu Ala 410 415 420 CTG TCC AGA ATTGCA GGT CTT TGT AAC AGG GCA GTG TTT CAG GCT 1305 Leu Ser Arg Ile Ala GlyLeu Cys Asn Arg Ala Val Phe Gln Ala 425 430 435 AAC CAG GAA AAC CTA CCTATT CTT AAG CGG GCA GTT GCA GGA GAT 1350 Asn Gln Glu Asn Leu Pro Ile LeuLys Arg Ala Val Ala Gly Asp 440 445 450 GCC TCT GAG TCA GCA CTC TTA AAGTGC ATA GAG CTG TGC TGT GGT 1395 Ala Ser Glu Ser Ala Leu Leu Lys Cys IleGlu Leu Cys Cys Gly 455 460 465 TTC GTG AAG GAG ATG AGA GAA AGA TAC GCCAAA ATC GTC GAG ATA 1440 Ser Val Lys Glu Met Arg Glu Arg Tyr Ala Lys IleVal Glu Ile 470 475 480 CCC TTC AAC TCC ACC AAC AAG TAC CAG TTG TCT ATTCAT AAG AAC 1485 Pro Phe Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His LysAsn 485 490 495 CCC AAC ACA TCG GAG CCC CAA CAC CTG TTG GTG ATG AAG GGCGCC 1530 Pro Asn Thr Ser Glu Pro Gln His Leu Leu Val Met Lys Gly Ala 500505 510 CCA GAA AGG ATC CTA GAC CGT TGC AGC TCT ATC CTC CTC CAC GGC 1575Pro Glu Arg Ile Leu Asp Arg Cys Ser Ser Ile Leu Leu His Gly 515 520 525AAG GAG CAG CCC CTG GAT GAG GAG CTG AAA GAC GCC TTT CAG AAC 1620 Lys GluGln Pro Leu Asp Glu Glu Leu Lys Asp Ala Phe Gln Asn 530 535 540 GCC TATTTG GAG CTG GGG GGC CTC GGA GAA CGA GTC CTA GGT TTC 1665 Ala Tyr Leu GluLeu Gly Gly Leu Gly Glu Arg Val Leu Gly Phe 545 550 555 TGC CAC CTC TTTCTG CCA GAT GAA CAG TTT CCT GAA GGG TTC CAG 1710 Cys His Leu Phe Leu ProAsp Glu Gln Phe Pro Glu Gly Phe Gln 560 565 570 TTT GAC ACT GAC GAT GTGAAT TTC CCT ATC GAT AAT CTG TGC TTC 1755 Phe Asp Thr Asp Asp Val Asn PhePro Ile Asp Asn Leu Cys Phe 575 580 585 GTT GGG CTC ATC TCC ATG ATT GACCCT CCA CGG GCG GCC GTT CCT 1800 Val Gly Leu Ile Ser Met Ile Asp Pro ProArg Ala Ala Val Pro 590 595 600 GAT GCC GTG GGC AAA TGT CGA AGT GCT GGAATT AAG GTC ATC ATG 1845 Asp Ala Val Gly Lys Cys Arg Ser Ala Gly Ile LysVal Ile Met 605 610 615 GTC ACA GGA GAC CAT CCA ATC ACA GCT AAA GCT ATTGCC AAA GGT 1890 Val Thr Gly Asp His Pro Ile Thr Ala Lys Ala Ile Ala LysGly 620 625 630 GTG GGC ATC ATC TCA GAA GGC ATG GAG ACC GTG GAA GAC ATTGCT 1935 Val Gly Ile Ile Ser Glu Gly Asn Glu Thr Val Glu Asp Ile Ala 635640 645 GCC CGC CTC AAC ATC CCA GTC AGC CAG GTG AAC CCC AGG GAT GCC 1980Ala Arg Leu Asn Ile Pro Val Ser Gln Val Asn Pro Arg Asp Ala 650 655 660AAG GCC TGC GTA GTA CAC GGC AGT GAT CTA AAG GAC ATG ACC TCC 2025 Lys AlaCys Val Val His Gly Ser Asp Leu Lys Asp Met Thr Ser 665 670 675 GAG CAGCTG GAT GAC ATT TTG AAG TAC CAC ACT GAG ATA GTG TTT 2070 Glu Gln Leu AspAsp Ile Leu Lys Tyr His Thr Glu Ile Val Phe 680 685 690 GCC AGG ACC TCCCCT CAG CAG AAG CTC ATC ATT GTG GAA GGC TGC 2115 Ala Arg Thr Ser Pro GlnGln Lys Leu Ile Ile Val Glu Gly Cys 695 700 705 CAA AGA CAG GGT GCT ATCGTG GCT GTG ACT GGT GAC GGT GTG AAT 2160 Gln Arg Gln Gly Ala Ile Val AlaVal Thr Gly Asp Gly Val Asn 710 715 720 GAC TCT CCA GCT TTG AAG AAA GCAGAC ATT GGG GTT GCT ATG GGG 2205 Asp Ser Pro Ala Leu Lys Lys Ala Asp IleGly Val Ala Met Gly 725 730 735 ATT GCT GGC TCA GAT GTG TCC AAG CAA GCTGCT GAC ATG ATT CTT 2250 Ile Ala Gly Ser Asp Val Ser Lys Gln Ala Ala AspMet Ile Leu 740 745 750 CTG GAT GAC AAC TTT GCC TCA ATT GTG ACT GGA GTAGAG GAA GGT 2295 Leu Asp Asp Asn Phe Ala Ser Ile Val Thr Gly Val Glu GluGly 755 760 765 CGT CTG ATC TTT GAT AAC TTG AAG AAA TCC ATT GCT TAT ACCTTA 2340 Arg Leu Ile Phe Asp Asn Leu Lys Lys Ser Ile Ala Tyr Thr Leu 770775 780 ACC AGT AAC ATT CCC GAG ATC ACC CCG TTC CTG ATA TTT ATT ATT 2385Thr Ser Asn Ile Pro Glu Ile Thr Pro Phe Leu Ile Phe Ile Ile 785 790 795GCA AAC ATT CCA CTA CCA CTG GGG ACT GTC ACC ATC CTC TGC ATT 2430 Ala AsnIle Pro Leu Pro Leu Gly Thr Val Thr Ile Leu Cys Ile 800 805 810 GAC TTGGGC ACT GAC ATG GTT CCT GCC ATC TCC CTG GCT TAT GAG 2475 Asp Leu Gly ThrAsp Met Val Pro Ala Ile Ser Leu Ala Tyr Glu 815 820 825 CAG GCT GAG AGTGAC ATC ATG AAG AGA CAG CCC AGA AAT CCC AAA 2520 Gln Ala Glu Ser Asp IleMet Lys Arg Gln Pro Arg Asn Pro Lys 830 835 840 ACA GAC AAA CTT GTG AATGAG CGG CTG ATC AGC ATG GCC TAT GGG 2565 Thr Asp Lys Leu Val Asn Glu ArgLeu Ile Ser Met Ala Tyr Gly 845 850 855 CAG ATT GGA ATG ATC CAG GCC CTGGGA GGC TTC TTT ACT TAC TTT 2610 Gln Ile Gly Met Ile Gln Ala Leu Gly GlyPhe Phe Thr Tyr Phe 860 865 870 GTG ATT CTG GCT GAG AAC GGC TTC CTC CCAATT CAC CTG TTG GGC 2655 Val Ile Leu Ala Glu Asn Gly Phe Leu Pro Ile HisLeu Leu Gly 875 880 885 CTC CGA GTG GAC TGG GAT GAC CGC TGG ATC AAC GATGTG GAA GAC 2700 Leu Arg Val Asp Trp Asp Asp Arg Trp Ile Asn Asp Val GluAsp 890 895 900 AGC TAC GGG CAG CAG TGG ACC TAT GAG CAG AGG AAA ATC GTGGAG 2745 Ser Tyr Gly Gln Gln Trp Thr Tyr Glu Gln Arg Lys Ile Val Glu 905910 915 TTC ACC TGC CAC ACA GCC TTC TTC GTC AGT ATC GTG GTG GTG CAG 2790Phe Thr Cys His Thr Ala Phe Phe Val Ser Ile Val Val Val Gln 920 925 930TGG GCC GAC TTG GTC ATC TGT AAG ACC AGG AGG AAT TCG GTC TTC 2835 Trp AlaAsp Leu Val Ile Cys Lys Thr Arg Arg Asn Ser Val Phe 935 940 945 CAG CAGGGG ATG AAG AAC AAG ATC TTG ATA TTT GGC CTC TTT GAA 2880 Gln Gln Gly MetLys Asn Lys Ile Leu Ile Phe Gly Leu Phe Glu 950 955 960 GAG ACA GCC CTGGCT GCT TTC CTT TCC TAC TGC CCT GGA ATG GGT 2925 Glu Thr Ala Leu Ala AlaPhe Leu Ser Tyr Cys Pro Gly Met Gly 965 970 975 GTT GCT CTT AGG ATG TATCCC CTC AAA CCT ACC TGG TGG TTC TGT 2970 Val Ala Leu Arg Met Tyr Pro LeuLys Pro Thr Trp Trp Phe Cys 980 985 990 GCC TTC CCC TAC TCT CTT CTC ATCTTC GTA TAT GAC GAA GTC AGA 3015 Ala Phe Pro Tyr Ser Leu Leu Ile Phe ValTyr Asp Glu Val Arg 995 1000 1005 AAA CTC ATC ATC AGG CGA CGC CCT GGCGGC TGG GTG GAG AAG GAA 3060 Lys Leu Ile Ile Arg Arg Arg Pro Gly Gly TrpVal Glu Lys Glu 1010 1015 1020 ACC TAC TAT 3069 Thr Tyr Tyr 1023 aminoacids amino acid single unknown 6 Met Gly Lys Gly Val Gly Arg Asp LysTyr Glu Pro Ala Ala Val 1 5 10 15 Ser Glu Gln Glu Asp Lys Lys Glu LysLys Glu Lys Lys Asp Arg 20 25 30 Asp Met Asp Glu Leu Lys Lys Glu Val SerMet Asp Asp His Lys 35 40 45 Leu Ser Leu Asp Glu Leu His Arg Lys Tyr GlyThr Asp Leu Ser 50 55 60 Arg Gly Leu Thr Ser Ala Arg Ala Ala Glu Ile LeuAla Arg Asp 65 70 75 Gly Pro Asn Ala Leu Thr Pro Pro Pro Thr Thr Pro GluTrp Ile 80 85 90 Lys Phe Cys Arg Gln Leu Phe Gly Gly Phe Ser Met Leu LeuTrp 95 100 105 Ile Gly Ala Ile Leu Cys Phe Leu Ala Tyr Ser Ile Gln AlaAla 110 115 120 Thr Glu Glu Glu Pro Gln Asn Asp Asn Leu Tyr Leu Gly ValVal 125 130 135 Leu Ser Ala Val Val Ile Ile Thr Gly Cys Phe Ser Tyr TyrGln 140 145 150 Glu Ala Lys Ser Ser Lys Ile Met Glu Ser Phe Lys Asn MetVal 155 160 165 Pro Gln Gln Ala Leu Val Ile Arg Asn Gly Glu Lys Met SerIle 170 175 180 Asn Ala Glu Glu Val Val Val Gly Asp Leu Val Glu Val LysGly 185 190 195 Gly Asp Arg Ile Pro Ala Asp Leu Arg Ile Ile Ser Ala AsnGly 200 205 210 Cys Lys Val Asp Asn Ser Ser Leu Thr Gly Glu Ser Glu ProGln 215 220 225 Thr Arg Ser Pro Asp Phe Thr Asn Glu Asn Pro Leu Glu ThrArg 230 235 240 Asn Ile Ala Phe Phe Ser Thr Asn Cys Val Glu Gly Thr AlaArg 245 250 255 Gly Ile Val Val Tyr Thr Gly Asp Arg Thr Val Met Gly ArgIle 260 265 270 Ala Thr Leu Ala Ser Gly Leu Glu Gly Gly Gln Thr Pro IleAla 275 280 285 Ala Glu Ile Glu His Phe Ile His Ile Ile Thr Gly Val AlaVal 290 295 300 Phe Leu Gly Val Ser Phe Phe Ile Leu Ser Leu Ile Leu GluTyr 305 310 315 Thr Trp Leu Glu Ala Val Ile Phe Leu Ile Gly Ile Ile ValAla 320 325 330 Asn Val Pro Glu Gly Leu Leu Ala Thr Val Thr Val Cys LeuThr 335 340 345 Leu Thr Ala Lys Arg Met Ala Arg Lys Asn Cys Leu Val LysAsn 350 355 360 Leu Glu Ala Val Glu Thr Leu Gly Ser Thr Ser Thr Ile CysSer 365 370 375 Asp Lys Thr Gly Thr Leu Thr Gln Asn Arg Met Thr Val AlaHis 380 385 390 Met Trp Phe Asp Asn Gln Ile His Glu Ala Asp Thr Thr GluAsn 395 400 405 Gln Ser Gly Val Ser Phe Asp Lys Thr Ser Ala Thr Trp LeuAla 410 415 420 Leu Ser Arg Ile Ala Gly Leu Cys Asn Arg Ala Val Phe GlnAla 425 430 435 Asn Gln Glu Asn Leu Pro Ile Leu Lys Arg Ala Val Ala GlyAsp 440 445 450 Ala Ser Glu Ser Ala Leu Leu Lys Cys Ile Glu Leu Cys CysGly 455 460 465 Ser Val Lys Glu Met Arg Glu Arg Tyr Ala Lys Ile Val GluIle 470 475 480 Pro Phe Asn Ser Thr Asn Lys Tyr Gln Leu Ser Ile His LysAsn 485 490 495 Pro Asn Thr Ser Glu Pro Gln His Leu Leu Val Met Lys GlyAla 500 505 510 Pro Glu Arg Ile Leu Asp Arg Cys Ser Ser Ile Leu Leu HisGly 515 520 525 Lys Glu Gln Pro Leu Asp Glu Glu Leu Lys Asp Ala Phe GlnAsn 530 535 540 Ala Tyr Leu Glu Leu Gly Gly Leu Gly Glu Arg Val Leu GlyPhe 545 550 555 Cys His Leu Phe Leu Pro Asp Glu Gln Phe Pro Glu Gly PheGln 560 565 570 Phe Asp Thr Asp Asp Val Asn Phe Pro Ile Asp Asn Leu CysPhe 575 580 585 Val Gly Leu Ile Ser Met Ile Asp Pro Pro Arg Ala Ala ValPro 590 595 600 Asp Ala Val Gly Lys Cys Arg Ser Ala Gly Ile Lys Val IleMet 605 610 615 Val Thr Gly Asp His Pro Ile Thr Ala Lys Ala Ile Ala LysGly 620 625 630 Val Gly Ile Ile Ser Glu Gly Asn Glu Thr Val Glu Asp IleAla 635 640 645 Ala Arg Leu Asn Ile Pro Val Ser Gln Val Asn Pro Arg AspAla 650 655 660 Lys Ala Cys Val Val His Gly Ser Asp Leu Lys Asp Met ThrSer 665 670 675 Glu Gln Leu Asp Asp Ile Leu Lys Tyr His Thr Glu Ile ValPhe 680 685 690 Ala Arg Thr Ser Pro Gln Gln Lys Leu Ile Ile Val Glu GlyCys 695 700 705 Gln Arg Gln Gly Ala Ile Val Ala Val Thr Gly Asp Gly ValAsn 710 715 720 Asp Ser Pro Ala Leu Lys Lys Ala Asp Ile Gly Val Ala MetGly 725 730 735 Ile Ala Gly Ser Asp Val Ser Lys Gln Ala Ala Asp Met IleLeu 740 745 750 Leu Asp Asp Asn Phe Ala Ser Ile Val Thr Gly Val Glu GluGly 755 760 765 Arg Leu Ile Phe Asp Asn Leu Lys Lys Ser Ile Ala Tyr ThrLeu 770 775 780 Thr Ser Asn Ile Pro Glu Ile Thr Pro Phe Leu Ile Phe IleIle 785 790 795 Ala Asn Ile Pro Leu Pro Leu Gly Thr Val Thr Ile Leu CysIle 800 805 810 Asp Leu Gly Thr Asp Met Val Pro Ala Ile Ser Leu Ala TyrGlu 815 820 825 Gln Ala Glu Ser Asp Ile Met Lys Arg Gln Pro Arg Asn ProLys 830 835 840 Thr Asp Lys Leu Val Asn Glu Arg Leu Ile Ser Met Ala TyrGly 845 850 855 Gln Ile Gly Met Ile Gln Ala Leu Gly Gly Phe Phe Thr TyrPhe 860 865 870 Val Ile Leu Ala Glu Asn Gly Phe Leu Pro Ile His Leu LeuGly 875 880 885 Leu Arg Val Asp Trp Asp Asp Arg Trp Ile Asn Asp Val GluAsp 890 895 900 Ser Tyr Gly Gln Gln Trp Thr Tyr Glu Gln Arg Lys Ile ValGlu 905 910 915 Phe Thr Cys His Thr Ala Phe Phe Val Ser Ile Val Val ValGln 920 925 930 Trp Ala Asp Leu Val Ile Cys Lys Thr Arg Arg Asn Ser ValPhe 935 940 945 Gln Gln Gly Met Lys Asn Lys Ile Leu Ile Phe Gly Leu PheGlu 950 955 960 Glu Thr Ala Leu Ala Ala Phe Leu Ser Tyr Cys Pro Gly MetGly 965 970 975 Val Ala Leu Arg Met Tyr Pro Leu Lys Pro Thr Trp Trp PheCys 980 985 990 Ala Phe Pro Tyr Ser Leu Leu Ile Phe Val Tyr Asp Glu ValArg 995 1000 1005 Lys Leu Ile Ile Arg Arg Arg Pro Gly Gly Trp Val GluLys Glu 1010 1015 1020 Thr Tyr Tyr 909 bases nucleic acid double linear7 ATG GCC CGC GGG AAA GCC AAG GAG GAG GGC AGC TGG AAG AAA TTC 45 Met AlaArg Gly Lys Ala Lys Glu Glu Gly Ser Trp Lys Lys Phe 1 5 10 15 ATC TGGAAC TCA GAG AAG AAG GAG TTT CTG GGC AGG ACC GGT GGC 90 Ile Trp Asn SerGlu Lys Lys Glu Phe Leu Gly Arg Thr Gly Gly 20 25 30 AGT TGG TTT AAG ATCCTT CTA TTC TAC GTA ATA TTT TAT GGC TGC 135 Ser Trp Phe Lys Ile Leu LeuPhe Tyr Val Ile Phe Tyr Gly Cys 35 40 45 CTG GCT GGC ATC TTC ATC GGA ACCATC CAA GTG ATG CTG CTC ACC 180 Leu Ala Gly Ile Phe Ile Gly Thr Ile GlnVal Met Leu Leu Thr 50 55 60 ATC AGT GAA TTT AAG CCC ACA TAT CAG GAC CGAGTG GCC CCG CCA 225 Ile Ser Glu Phe Lys Pro Thr Tyr Gln Asp Arg Val AlaPro Pro 65 70 75 GGA TTA ACA CAG ATT CCT CAG ATC CAG AAG ACT GAA ATT TCCTTT 270 Gly Leu Thr Gln Ile Pro Gln Ile Gln Lys Thr Glu Ile Ser Phe 8085 90 CGT CCT AAT GAT CCC AAG AGC TAT GAG GCA TAT GTA CTG AAC ATA 315Arg Pro Asn Asp Pro Lys Ser Tyr Glu Ala Tyr Val Leu Asn Ile 95 100 105GTT AGG TTC CTG GAA AAG TAC AAA GAT TCA GCC CAG AGG GAT GAC 360 Val ArgPhe Leu Glu Lys Tyr Lys Asp Ser Ala Gln Arg Asp Asp 110 115 120 ATG ATTTTT GAA GAT TGT GGC GAT GTG CCC AGT GAA CCG AAA GAA 405 Met Ile Phe GluAsp Cys Gly Asp Val Pro Ser Glu Pro Lys Glu 125 130 135 CGA GGA GAC TTTAAT CAT GAA CGA GGA GAG CGA AAG GTC TGC AGA 450 Arg Gly Asp Phe Asn HisGlu Arg Gly Glu Arg Lys Val Cys Arg 140 145 150 TTC AAG CTT GAA TGG CTGGGA AAT TGC TCT GGA TTA AAT GAT GAA 495 Phe Lys Leu Glu Trp Leu Gly AsnCys Ser Gly Leu Asn Asp Glu 155 160 165 ACT TAT GGC TAC AAA GAG GGC AAACCG TGC ATT ATT ATA AAG CTC 540 Thr Tyr Gly Tyr Lys Glu Gly Lys Pro CysIle Ile Ile Lys Leu 170 175 180 AAC CGA GTT CTA GGC TTC AAA CCT AAG CCTCCC AAG AAT GAG TCC 585 Asn Arg Val Leu Gly Phe Lys Pro Lys Pro Pro LysAsn Glu Ser 185 190 195 TTG GAG ACT TAC CCA GTG ATG AAG TAT AAC CCA AATGTC CTT CCC 630 Leu Glu Thr Tyr Pro Val Met Lys Tyr Asn Pro Asn Val LeuPro 200 205 210 GTT CAG TGC ACT GGC AAG CGA GAT GAA GAT AAG GAT AAA GTTGGA 675 Val Gln Cys Thr Gly Lys Arg Asp Glu Asp Lys Asp Lys Val Gly 215220 225 AAT GTG GAG TAT TTT GGA CTG GGC AAC TCC CCT GGT TTT CCT CTG 720Asn Val Glu Tyr Phe Gly Leu Gly Asn Ser Pro Gly Phe Pro Leu 230 235 240CAG TAT TAT CCG TAC TAT GGC AAA CTC CTG CAG CCC AAA TAC CTG 765 Gln TyrTyr Pro Tyr Tyr Gly Lys Leu Leu Gln Pro Lys Tyr Leu 245 250 255 CAG CCCCTG CTG GCC GTA CAG TTC ACC AAT CTT ACC ATG GAC ACT 810 Gln Pro Leu LeuAla Val Gln Phe Thr Asn Leu Thr Met Asp Thr 260 265 270 GAA ATT CGC ATAGAG TGT AAG GCG TAC GGT GAG AAC ATT GGG TAC 855 Glu Ile Arg Ile Glu CysLys Ala Tyr Gly Glu Asn Ile Gly Tyr 275 280 285 AGT GAG AAA GAC CGT TTTCAG GGA CGT TTT GAT GTA AAA ATT GAA 900 Ser Glu Lys Asp Arg Phe Gln GlyArg Phe Asp Val Lys Ile Glu 290 295 300 GTT AAG AGC 909 Val Lys Ser 303amino acids amino acid single unknown 8 Met Ala Arg Gly Lys Ala Lys GluGlu Gly Ser Trp Lys Lys Phe 1 5 10 15 Ile Trp Asn Ser Glu Lys Lys GluPhe Leu Gly Arg Thr Gly Gly 20 25 30 Ser Trp Phe Lys Ile Leu Leu Phe TyrVal Ile Phe Tyr Gly Cys 35 40 45 Leu Ala Gly Ile Phe Ile Gly Thr Ile GlnVal Met Leu Leu Thr 50 55 60 Ile Ser Glu Phe Lys Pro Thr Tyr Gln Asp ArgVal Ala Pro Pro 65 70 75 Gly Leu Thr Gln Ile Pro Gln Ile Gln Lys Thr GluIle Ser Phe 80 85 90 Arg Pro Asn Asp Pro Lys Ser Tyr Glu Ala Tyr Val LeuAsn Ile 95 100 105 Val Arg Phe Leu Glu Lys Tyr Lys Asp Ser Ala Gln ArgAsp Asp 110 115 120 Met Ile Phe Glu Asp Cys Gly Asp Val Pro Ser Glu ProLys Glu 125 130 135 Arg Gly Asp Phe Asn His Glu Arg Gly Glu Arg Lys ValCys Arg 140 145 150 Phe Lys Leu Glu Trp Leu Gly Asn Cys Ser Gly Leu AsnAsp Glu 155 160 165 Thr Tyr Gly Tyr Lys Glu Gly Lys Pro Cys Ile Ile IleLys Leu 170 175 180 Asn Arg Val Leu Gly Phe Lys Pro Lys Pro Pro Lys AsnGlu Ser 185 190 195 Leu Glu Thr Tyr Pro Val Met Lys Tyr Asn Pro Asn ValLeu Pro 200 205 210 Val Gln Cys Thr Gly Lys Arg Asp Glu Asp Lys Asp LysVal Gly 215 220 225 Asn Val Glu Tyr Phe Gly Leu Gly Asn Ser Pro Gly PhePro Leu 230 235 240 Gln Tyr Tyr Pro Tyr Tyr Gly Lys Leu Leu Gln Pro LysTyr Leu 245 250 255 Gln Pro Leu Leu Ala Val Gln Phe Thr Asn Leu Thr MetAsp Thr 260 265 270 Glu Ile Arg Ile Glu Cys Lys Ala Tyr Gly Glu Asn IleGly Tyr 275 280 285 Ser Glu Lys Asp Arg Phe Gln Gly Arg Phe Asp Val LysIle Glu 290 295 300 Val Lys Ser 24 bases nucleic acid single linear 9ATGGGGAAGG GGGTTGGACG TGAT 24 24 bases nucleic acid single linear 10ATAGTAGGTT TCCTTCTCCA CCCA 24 24 bases nucleic acid single linear 11ATGGCCCGCG GGAAAGCCAA GGAG 24 24 bases nucleic acid single linear 12GCTCTTAACT TCAATTTTTA CATC 24

What is claimed is:
 1. A delivery system for delivering a predeterminedgenetic material or protein to myocardial cells of a selected locationof a patient's heart, comprising: a sensor for locating an area ofinadequate P-wave production in the heart of a patient; and a deliverymeans for delivering a supply of said genetic material or protein tosaid selected location in said patients heart wherein said geneticmaterial is selected from the group consisting of DNA encoding an ionchannel protein, RNA encoding an ion channel protein, and an ion channelprotein.
 2. The delivery system of claim 1, wherein said delivery meansfurther comprises a catheter.
 3. The delivery system of claim 1, whereinsaid catheter is an endocardial catheter.
 4. The delivery system ofclaim 2, wherein said delivery means comprises a hollow helical screw-inelement.
 5. The delivery system of claim 1, wherein said supply ofgenetic material is provided as a bolus to said selected location. 6.The delivery system of claim 1, wherein the delivery means forms part ofthe sensor.
 7. The delivery system of claim 1, where the delivery meansis not part of the sensor.
 8. The deivery system of claim 1, whereinsaid selected genetic material is a recombinant nucleic acid moleculeencoding the ion channel protein.
 9. The delivery system of claim 8,wherein said ion channel protein is a sodium channel protein.
 10. Thedelivery system of claim 9, wherein sodium channel protein is hH1. 11.The delivery system of claim 1, wherein said genetic material or proteinincreases the amplitude of the cardiac signal of said patient's heart.12. An implantable delivery system for delivering doses of predeterminedgenetic material or protein to myocardial cells in a chosen location ofa patient's heart, comprising: a sensor for detecting cardiac signalsfrom said chosen location; a supply of genetic material or proteinselected from group consisting of DNA encoding an ion channel protein,RNA encoding an ion channel protein, and an ion channel protein; and animplantable delivery means for delivering said genetic material orprotein to said chosen location.
 13. The implantable delivery system asdescribed in claim 12, further comprising a control means forcontrolling operation of said delivery means.
 14. The implantabledelivery system of claim 12, wherein said controlling means controls therate of delivery of said doses.
 15. The implantable delivery system ofclaim 12, wherein said control means comprises automatic means forautomatically initiating delivery of said genetic material.
 16. Thedelivery system of claim 12, wherein said genetic material or proteinincreases the amplitude of the cardiac signal of said patient's heart.17. The delivery system of claim 12, wherein said supply of geneticmaterial is provided as a bolus to said selected location.
 18. Thedelivery system of claim 12, wherein said selected general material is arecombinant nucleic acid molecule encoding the ion channel protein. 19.The delivery system of claim 18, wherein said ion channel protein is asodium channel protein.
 20. The delivery system of claim 19, whereinsaid sodium channel protein is hH1.
 21. An implantable delivery systemfor delivering predetermined genetic material or protein to cardiaccells adjacent to a pacing electrode positioned in the heart of apatient, comprising: a supply of genetic material or protein selectedfrom the group consisting of DNA encoding an ion channel protein, RNAencoding an ion channel protein, and an ion channel protein; a pacingelectrode adapted to be positioned in the heart of a patient; and adelivery means for delivering said genetic material or protein to saidcardiac cells adjacent to said pacing electrode positioned in the heartof a patient.
 22. The implantable delivery system of claim 21 whereinthe pacing electrode is positioned against the inner wall of a patient'sheart.
 23. The implantable delivery system of claim 21, wherein saiddelivery means forms part of said pacing electrode.
 24. The system asdescribed in claim 21, further comprises a control means for controllingoperation of said delivery means to deliver said genetic material orprotein.
 25. The implantable delivery system of claim 21, furthercomprising a control means for controlling the rate of delivery of saiddoses.
 26. The implantable delivery system of claim 21, wherein saidcontrol means comprises automatic means for initiating delivery of saidgenetic material.
 27. The delivery system of claim 21, wherein saidgenetic material or protein increases the amplitude of the cardiacsignal of said patient's heart.
 28. The delivery system of claim 21,wherein said delivery means comprises a hollow helical screw-in element.29. The delivery system of claim 21, wherein the delivery means formspart of the sensor.
 30. The delivery system of claim 21, wherein saidsupply of genetic material is provided as a bolus to said selectedlocation.
 31. The delivery system of claim 21, wherein said selectedgenetic material is a recombinant nucleic acid molecule encoding the ionchannel protein.
 32. The delivery system of claim 31, wherein said ionchannel protein is a sodium channel protein.
 33. The delivery system ofclaim 32, wherein said sodium channel protein is hH1.